PF-[ADDRESS_207703] Number: PF-[ADDRESS_207704] Name: [CONTACT_82111] (N/A)[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:N/A
Protocol Number: C3421012
Phase: 1Short Title: Pharmacokinetic Study of PF-06882961 in  Participants With Type 2 Diabetes 
Mellitus With Varying Degrees of Renal Impairment and Participants Without Renal Impairment
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
promptly notified.CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Original protocol 13 Octobe r 2020 N/A

PF-[ADDRESS_207705] OF TABLES................................................................................................................. ....8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 12
1.3. Schedule of Activities (SoA)...................................................................................13
2. INTRODUCTION ...............................................................................................................15
2.1. Study R ationale .......................................................................................................15
2.2. Background .............................................................................................................15
2.2.1. Nonclinical Pharmacology..........................................................................16
2.2.3. Nonclinical Safety ......................................................................................17
2.2.4. Clinical Overview.......................................................................................17
[IP_ADDRESS]. Clinical Safety...........................................................................[IP_ADDRESS]. Clinical Pharmacokinetics.........................................................18
2.3. Benefit/Risk Assessment.........................................................................................19
3. OBJECTIVES AND ENDPOINTS .....................................................................................204. STUDY DESIGN................................................................................................................ .21
4.1. Overall Design.........................................................................................................21
4.2. Scientific Rationale for Study Design.....................................................................234.3. Justification for Dose ..............................................................................................244.4. End of Study Definition ..........................................................................................25
5. STUDY POPULATION ......................................................................................................25
5.1. Inclusion Criteria.....................................................................................................25
5.1.1. Inclusion Criteria for All Participants.........................................................255.1.2. Additional Inclusion Criteria for Healthy Participants with Normal 
Renal Function (Group 1) ................................................................................26
5.1.3. Additional Inclusion Criteria for T2DM Participants with Normal 
Renal Function (Group 2) ................................................................................26
5.1.4. Additional Inclusion Criteria for T2DM Participants with Impaired 
Renal Function (Groups 3-5) ...........................................................................27
5.2. Exclusion Criteria....................................................................................................27
5.2.1. Exclusion Criteria for All Participants .......................................................27CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 45.2.2. Additional Exclusion Criteria for Health y Participants with Normal 
Renal Function (Group 1) ................................ ................................ ................ 30
5.2.3. Additional Exclusion Criteria for T2DM Participants with Normal 
Renal Function (Group 2) ................................................................................30
5.2.4. Additional Exclusion Criteria for T2DM Participant s with I mpaired 
Renal Function (Groups 3
-5) only ...................................................................30
5.2.5. Criteria for Dosing on Day  1
......................................................................31
5.3.Lifesty le Considerations ..........................................................................................31
5.3.1. Meals and Dietary  Restrictions ...................................................................31
5.3.2. Caffeine, Alc ohol, and Tobacco .................................................................32
5.3.3. Activity .......................................................................................................32
5.3.4. Contraception ..............................................................................................32
5.4. Screen Failures ........................................................................................................33
6. STUDY INTERVENTIO N
..................................................................................................33
6.1. Study  Intervention Administered ............................................................................33
6.1.1. Administration ............................................................................................33
6.2. Preparation/Handling/Storage/Ac countability ........................................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Measures to Minim ize Bias: Randomization and Blinding .....................................[ADDRESS_207706] .........................................................35
6.4. Study  Intervention Compliance ...............................................................................35
6.5. Concomitant Therapy ..............................................................................................35
6.5.1. Rescue Medicine .........................................................................................36
6.6. Dose Modification ...................................................................................................36
6.7. I ntervention After the End of the Study ..................................................................36
7. DI SCONTIN UAT ION OF STUDY INTE RVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRA WAL ...........................................................................36
7.1. Discontinuation of Study  Intervention ....................................................................36
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_207707] to Follow up ....................................................................................................38
8. STUDY ASSESSMENTS AND PROC EDURES ...............................................................38
8.1. Efficacy  Assessments ..............................................................................................39

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 58.2. Safet y Assessments .................................................................................................39
8.2.1. Phy sical Examinations ................................................................................39
8.2.2. Vital Signs ..................................................................................................40
[IP_ADDRESS]. Temperature ..............................................................................40
8.2.3. Electrocardiograms
.....................................................................................40
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................41
8.2.5. Gluco
meter Monitoring of Glucose............................................................41
8.2.6. Management of Hy pogly cemia ...................................................................42
[IP_ADDRESS]. Definition and Severit y of Categorization of 
Hypoglycemic Adverse Event (HAE) ...............................................42
8.2.7. Management of Hy pergly cemia .................................................................43
8.2.8. Pregnancy  Testi
ng ......................................................................................44
8.2.9. COVID -19 Specific Assessments...............................................................44
8.3. Adverse Events and Serious Adverse Events
..........................................................44
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......44
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................45
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................45
8.3.2. Method of Detecting AEs and SAEs ..........................................................45
8.3.3. Follow -up of AEs and SAEs .......................................................................46
8.3.4. Regulatory  Report ing Requirements for SAEs ...........................................46
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................46
[IP_ADDRESS]. Exposure During Pregnancy ................................ ...................... 47
[IP_ADDRESS]. Exposure During Breastfeeding ................................................47
[IP_ADDRESS]. Occupational Exposure .............................................................47
8.3.6. Cardiovascular and Death Events ...............................................................47
8.3.7. Disease -
Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_207708] ................................ ............................. 47
[IP_ADDRESS]. Lack of Efficacy ........................................................................47
8.3.9. Medical Device Deficiencies
................................ ................................ ......48
8.3.10. Medication Errors .....................................................................................48

PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 68.4. Treatment of Overdose............................................................................................48
8.5. Pharmacokinetics ....................................................................................................49
8.5.1. Plasma for Analysis of PF-06882961.........................................................498.5.2. Plasma for Determination of PF-06882961 Unbound Fraction..................508.5.3. Urine for Analysis of PF-06882961 ...........................................................50
8.6. Pharmaco dynamics..................................................................................................51
8.7. Pharmacogenomics..................................................................................................51
8.8. Biomarkers ..............................................................................................................51
8.8.1. Exploratory Biomarker for Measurement of CP-I......................................51
8.9. Health Economics ...................................................................................................52
9. STATISTICAL CONSIDERATIONS ................................................................................52
9.1. Statistical Hypotheses .............................................................................................52
9.2. Sample Size Determination.....................................................................................529.3. Populations for Analysis .........................................................................................539.4. Statistical Analyses .................................................................................................53
9.4.1. Efficacy Analyses .......................................................................................539.4.2. Safety Analys es ..........................................................................................53
[IP_ADDRESS]. Electrocardiogram Analyses......................................................54
9.4.3. Other Analyses............................................................................................54
[IP_ADDRESS]. Pharmacokinetic Analyses ........................................................54
9.5. Interim Analyses .....................................................................................................57
9.5.1. Data Monitoring Committee.......................................................................57
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................58
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............58
10.1.1. Regulatory and Ethical Considerations ....................................................58
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................58
10.1.2. Financial Disclosure .................................................................................5910.1.3. Informed Consent Process ........................................................................59
10.1.4. Data Protection .........................................................................................60CCI
PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 710.1.5. Dissemination of Clinical Study Data ......................................................60
10.1.6. Data Qualit y Assurance ............................................................................62
10.1.7. Source Documents....................................................................................6310.1.8. Study and Site Closure..............................................................................63
10.1.9. Publication Policy.....................................................................................6410.1.10. Sponsor’s Qualified Medical Personnel .................................................65
10.2. Appendix 2: Clinical Laboratory Tests .................................................................6610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................69
10.3.1. Definition of AE .......................................................................................6910.3.2. Definition of SAE.....................................................................................7010.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................7110.3.4. Reporting of SAEs....................................................................................74
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................76
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7610.4.2. Female Participant Reproductive Inclusion Criteria.................................7610.4.3. Woman of Childbearing Potential (WOCBP) ..........................................7610.4.4. Contraception Methods.............................................................................77
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........81
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................8310.8. Appendix 8: Prohibited Prior/Concomitant Medications......................................8510.9. Appendix 9: Proposed Chronology of Procedures................................................8610.10. Appendix 10: Abbreviations ...............................................................................[ADDRESS_207709] OF TABLES
Table 1. Study  Groups ................................ ................................ ............................ 21
Table 2. Expected Widths of the 90% CI s (with 80% Coverage Probability ) 
for Different Possible Estimated Effects ..................................................52
Table 3. Plasma PK Parameters ..............................................................................55
Table 4. Urine PK Parameters ................................................................................56
Table 5. Protocol -Required Safet y Laborat ory Assessments .................................67

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: Pharmacokinetic S tudy of PF-[ADDRESS_207710] of vary ing degrees of renal impairment on the pharmacokinetics (PK), safet y and 
tolerability  of a single oral dose of PF -06882961 in par ticipants with type 2 diabetes m ellitus 
(T2DM ), compared with participants with normal renal function.
Objectives and Endpoints
Objectives Endpoints
Prim ary: Prim ary: 
To compare the PKof PF -06882961 follow ing 
administration of a single oral dose in ad ult 
participants with T2DM and varying degrees of 
renal impairment relative to T2DM participants 
without renal impairment.Plasma: C max, AUC inf, AUC last, fu,as data permit .
Secondary: Secondar y: 
To compare additional PK parameters of 
PF-06882961 follo wing administration of a 
single oral dose in adult participants with 
T2DM and varying degrees of renal impairment 
relative to T2DM participants without renal 
impairm ent.Plasma: C max,u, AUC inf,u, AUC last,u, CL/F, CL u/F, 
Vz/F, V z,u/F, T max, t1/2, as data permit.
To evaluate the safety and tolerability of a 
single oral dose of PF -06882961 in T2DM 
participants with varying degrees of renal 
impairm ent and in participants with normal 
renal function.Incidence and severity of treatment -emergent 
AEs, clinical lab oratory abnormalities, vital signs 
(blood pressure and pulse rate) , 12-lead 
electrocardiogram ( ECG )parameters (heart rate, 
QT, QTcF, PR and QRS intervals) .
Tertiary/Exploratory: Tertiary/Exploratory: 
To compare urine PK param eters of 
PF-06882961 follo wing administration of a 
single oral dose in adult participants with 
T2DM and varying degrees of renal impairment 
relative to T2DM participants without renal 
impairm ent.Urine: CL r, Ae 24, Ae 24%.
To compare the PKof PF -06882961 follow ing 
administration of a single oral dose in adult 
participants with T2DM and normal renal 
function relative to healthy participants with 
norm al renal function.Plasma: C max, Tmax, AUC inf, AUC last, CL/F, V z/F, 
t1/2, fu,as data permit ;
Urine: CL r, Ae 24, Ae 24%.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 10To explore the relationship of markers of innate 
organic anion transporting polypeptide ( OATP )
activity in adult participants with T2DM and 
varying degrees of renal impairment relative to 
participants with normal renal function.Coproporphyrin I (CP- I)conc entration .
To enable exploratory research through 
collection of banked biospecimens, unless 
prohibited by [CONTACT_168038].Potential results from exploratory analysis of 
banked biospecimens (these results may or may 
not be g enerated in the context of the present 
study).
Overall Design
This Phase 1, open- label, sing le-dose, parallel group, multi -site study  will assess the effect of 
varying degrees of renal impairment on the PK, safety  and tolerability  ofPF-06882961 after 
a single oral dose of 20 mg administered in a fed state (Section 5.3.1 ).
Number of Participants
Approximately  [ADDRESS_207711] ( IP)and who take at least 1 dose of IP will be evaluable.  Participants 
who discontinue from the study  before completing all assessments may be replaced at the 
discretion of the investigator and sponsor.
Intervention Groups and Duration
Parti cipant s with T2DM and varying degrees of renal impairment (Group 3 : T2DM with mild 
renal impairment, Group 4: T2DM with moderate renal impairment, Group 5: T2DM with 
severe renal impairment
) will be recruited and enrolled first.  An average value for age a nd 
weight for t hese gr oups will be determined and participants in Groups 1-2 (Group 1: health y 
with normal renal function, Group 2: T2DM with normal renal function) will be recruited last 
to match the average demographics (at a minimum, age and weight, and, as much as 
practical ly possible ,
gender) across the pooled Groups 3- 5.  Approval from the sponsor must 
be garnered 
before proceeding with dosing participants in Groups [ADDRESS_207712] will be a minimum of approximately  5weeks and a maximum 
of approximately  10weeks.
Data Monitoring Committee: No
Statistical Methods
Linear regression will be used to characterize the potential relationship be tween appropria te 
PK parameters (CL /F, CL u/F and CL r) for PF -06882961 and renal function (eGFR). 

PF-[ADDRESS_207713] anal ysis of variance (ANOVA) will be used to compare the natural log 
transformed AUC inf(if data permit), AUC last, Cmaxand fu of PF -06882961 for ea ch of the 
T2DM renal impairment groups (Test, Groups 3, 4, 5 ) to the T2DM normal renal function 
group (Reference , Group 2). Also, the T2DM normal renal function group (Test , Group 2) 
will be compared to the healthy  normal renal funct ion group (Reference , Group 1). The 
ANOVA model will include all groups ( ie,both T2DM and healthy  participants from the 
5groups). Estimates of the adjusted mean differences (Test -Reference) and corresponding 
90% confidence intervals ( CIs)will be obtai ned from the model. T he adjusted mea n 
differences and 90% CIs for the differences will be exponentiated to provide estimates of the 
ratio of adjusted geometric means (Test/Reference) and corresponding 90% CI s.If 
substantial differences in demographic characteristics between healthy (Group 1) , T2DM 
normal (Group 2) and T2DM renal impairment function participants (Groups 3, 4, 5) are 
observed, covariates such as weight and age may  be explored.
The PK parameters for PF- 06882961 will also be summarized descr iptively  by [CONTACT_177261] (healthy  vs. T2DM). 
For summary  statistics and median/mean plots by [CONTACT_31065], the nominal PK sampling 
time will be used. For individual participant plots by  [CONTACT_5586], the actual PK sampling time will 
be use d.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 121.2.Schema
*Screen ing peri odis ≤[ADDRESS_207714] 
72 hours.Screen ing
Visit 1
(S1)Screen ing
Visit 2
(S2)Day -[ADDRESS_207715]
(28-35 days) 
post IP doseDay 2 Day 1
IP DosingDay 3
Discharge 
from CRUInpatient Study Period (Day -1 to Day 3)

PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 131.3. Schedule of Activities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to STUDY ASSESSMENTS AND PROCEDURES
Section 8.2 of the protocol for detailed information on each procedure and assessment required for compliance with the protocol. The 
investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, to conduct evaluations or assessments 
required to protect the well-being of the participant.
Visit Identifier (for proposed chronology of 
procedures refer to Appendix 9 ; for abbreviations 
refer to Appendix 10 )Screening Study Period Follow-
upbET
S1aS2a
Study Day ≤-[ADDRESS_207716] Dose -- -- -- 0 1 2 3 4 5 6 8 10 12 16 24 36 48
Informed consent & demography X
Adverse event monitoring X X X →→→→→→→→→→→→ →→ XX
Outpatient visit X X XbX
COVID-19 symptoms and risk assessment X X
COVID-19 testing XcX
Inpatient stay at Clinical Research Unit X →→→→→→→→→→→→ → X
Eligibility assessment X X
Medical history X X
Alcohol/tobacco & contraception use X X
Review contraception use (females only) X X X
Prior/concomitant treatments X X X
Physical exam (height and body weight at S1, only)dXX XX
Alcohol breath testeXX
Single, supi[INVESTIGATOR_050] 12-lead ECG XX X X
Single, seated vital sign assessmentfXXgXX X X
Glucometer measurementhXX X X
Standard mealsiXX X X X X
Investigational product administrationjXj
Blood Sampling for: 
Safety laboratory tests - after ≥8-hr fast (incl. eGFR)k,lXXlXX X
Serum FSH (females only), HbA1C, C- peptide X
Serum pregnancy test (WOCBP only)l,mXX X X
Exploratory plasma for coproporphyrin -I X
PF-06882961 PK X X X X X X X X X X X X X X X
PF-06882961 unbound fraction for protein binding X XCCI CCI
PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 14Visit Identifier (for proposed chronology of 
procedures refer to Appendix 9 ; for abbreviations 
refer to Appendix 10 )Screening Study Period Follow-
upbET
S1aS2a
Study Day ≤-[ADDRESS_207717] Dose -- -- -- 0 1 2 3 4 5 6 8 10 12 16 24 36 48
Urine Sampling for: 
Urine drug testoX
Urinalysis (and microscopy, if needed)pXX X X
On-site pregnancy test (WOCBP only)mX
PF-06882961 PKqX→→→→→ X→→ X→ X
a. Screening visits S1 and S2 should be separated by [CONTACT_2669] [ADDRESS_207718] result prior to admission on Day -1.
d. Full physical examination (PE) will be performed at Screening visit S1; at all other time points, a brief physical examinatio n is performed and may be performed at 
non-specified visits if there are findings during the previous exam or new/open AEs, if appropriate and at investigator discret ion.
e. Alcohol breath test may be conducted at investigator discretion.
f. Includes blood pressure, temperature and pulse rate.
g. On Day -1, only temperature is required on admission.h. Glucometer measures will be taken before breakfast in participants with T2DM on all days while inpatient.  Additional measure ments may be made at the discretion of the 
investigator.
i. Meals/snacks will occur on all days while inpatient as per Section 5.3.[ADDRESS_207719] on Day 1.k. The eGFR determination will be performed by [CONTACT_6626]. l. Only serum creatinine and eGFR (along with pregnancy testing) should be collected at S2. 
m. Test result must be reviewed and deemed acceptable (ie, negative) to continue participation in the study. For a participant o n dialysis who is anuric only, an alternative 
method (eg, blood) for urine pregnancy testing may be used.
o. For a participant on dialysis who is anuric only, an alternative method (eg, saliva) for drug testing may be used.
p. For a participant on dialysis who is anuric only, urinalysis is not required to be collected.
q. Blank pre-dose urine sample to be collected within 24H prior to dosing and urine should be collected at intervals of 0-6, 6-12  and 12-24 hours after dosing. If participant is on 
dialysis and has no urine output, no urine PK sample will be collected.CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 152.INTRODUCTIO N
Glucagon -like peptide- 1 (GL P-1) is a neuroendocrine hormone that is predominantly  
released from the small intestine in response to food intake.1GLP-1 activation of the GL P-1 
receptor (GLP -1R) stimulates insu lin release, inhibits glucagon secretion in a 
glucose -dependent manner, and delay s gastric empty ing.2,[ADDRESS_207720] approved for the treatment of t ype2 diabetes 
mellitus (T2DM ).
2.1.Study Rationale
The purpose of this multi- site, Phase 1, open -label, parallel -group stud y is to characterize the 
effect of var ying degrees of renal impairment on the PK, safet y and tolerability of a single 
oral dose of PF- [ADDRESS_207721] more than 424 million people 
worldwide,6and the prevalence of T2DM within the [LOCATION_002] ( US) is estimated to range 
from 12 to 14%.7  T2DM is characterized by [CONTACT_30361], a disorder in which cells do 
not respond effectivel y to ins
ulin, resulting in higher blood glucose leve ls.  Elevated blood 
glucose levels and increasing severity  of insulin resistance result in t he need for more insulin 
over time, eventuall y resulting in progressive pancreatic -cell failure.[ADDRESS_207722] an i ncreased risk of developi[INVESTIGATOR_177246], including nephropathy , neuropathy , retinopath y, 
cardiovascular disease and stroke; and are at [ADDRESS_207723] diabetes.9  While existing pharmacological options for the treatment 
of diabetes may  provide satisfactory  glycemic control for some pati
ents, there remains a large 
number of patients who do not achieve target gl ycated hemoglobin (HbA1c) lev els, 
suggesting a need for additional therapeutic options.
Marketed injectable GLP -1R agonists have demonstrated robust gly cemic efficacy , weight 
loss, and cardiovascular safet y, with some agent s demonstrating cardiovascular benefit.[ADDRESS_207724] is 
expected to improve glucose control and reduce HbA1c levels in patients with T2DM, while 
decreasing food intake and body  weight and avoiding the subcutaneous injection required by  
[CONTACT_107072] y available peptidic GL P-1R agonists.

PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 162.2.1. Nonclinical Pharmacology
In vitro primary pharmacodynamics (PD) studies demonstrated that, in cells expressing 
recombinant human and cynomolgus monkey GLP-1R, PF-06882961 dose-dependently promotes 3’-5’-cyclic adenosine monophosphate (cAMP) production.  In vivo, PF-[ADDRESS_207725] (IVGTT) in cynomolgus monkeys in a dose and concentration dependent manner.  PF-06882961 was also shown to reduce food intake in cynomolgus monkeys.  In all in vivo studies, efficacious plasma levels were consistent with the in vitro potency.  
Refer to the Investigator’s Brochure (IB) for more details on the nonclinical pharmacology of 
PF-06882961.
CCI
CCI
PF-[ADDRESS_207726] been completed in cynomolgus monkeys up to 6 months in 
duration (with a 3-week lead-in and 1-month recovery) and in rats up to 6 months in duration (with a 1‑month recovery).  The exposure limits for plasma concentrations of PF -[ADDRESS_207727] level (NOAEL) dose of 250 mg/kg/day in the 6-month w ith 1-month recovery toxicology study in 
rats, due to the fact that findings in monkeys such as decreased food intake and body weight loss are reversible and monitorable in a clinical setting.  In the 6-month toxicity study in rats with 1-month recovery, the NOAEL was 250 mg/kg/day based on species-specific toxicity at a higher dose. 
Embryo-fetal developmental studies were completed in rats and rabbits. Based on the lack of 
maternal toxicity or adverse effects on embryo-fetal development, the NOAEL for maternal and developmental toxicity in rats was 500 mg/kg/day (highest dose evaluated). In embryo-fetal studies conducted in rabbits, the NOAEL for maternal and developmental toxicity was 250 mg/kg/day.
PF-[ADDRESS_207728] completed dosing with 
PF-06882961. In C3421001 and C3421003, single oral doses of PF-06882961 up to 300 mg (or matching placebo) were generally safe and well tolerated in healthy adult participants.  In the multiple dose study C3421002, PF-06882961 doses up to 120 mg BID (or matching placebo) for 28 days were generally safe and well-tolerated in adult participants with T2DM on a background of metformin therapy, and safety results from this study are provided in 
Section [IP_ADDRESS] . Refer to the IB for more details on these studies and the known drug class 
effects of marketed injectable GLP-1R agonists.
[IP_ADDRESS]. Clinical Safety
Clinical data from the completed C3421001, C3421002, and C3421003 studies are provided 
in the IB for PF-06882961.CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 18In stud y C3421002, PF -06882961 doses ranging from 10 mg BID to 120 mg BID were 
generall y safe and well tolerated. A total of 98 participants with T2DM on a background of 
metformin were randomiz ed to receive PF -06882961 or matching placebo in a 
3:1randomization ratio, and 92 participants completed the study . Six participants 
discontinued from the study, of which 2 discontinuations were due to treatment-related 
TEAEs, and 4 withdrew during the t reatment or follow -up period for non -treatment related 
reasons.
A total of 319 all -causality treatment -emergent adverse events (TEAEs) were reported in 
these participants, of which a majority (294 or 92%) were mild in intensity, 23 (or 7%) were 
moderate, a nd 2 (or 1%) were severe in i ntensity . 
The total number of TEAEs generall y increased with higher dail y doses of PF -06882961. 
The most frequentl y reported TEAEs (b y number of occurrences) in these cohorts have been 
nausea (48), dy spepsia (32), vomiting (2 6), diarrhea (24), headache ( 23), constipation (20), 
and decreased appetite (19). In addition, there was one s ymptomatic hy poglycemic AE 
reported in 1 participant in the 120 mg BID group. This AE was non- fasting, mild in 
severit y, and of limited duration (15 minutes) . No deaths occ urred in the C3421002 study .
Two participants experienced 2 severe TEAEs during the stud y, 1 of which occurred in the 
dosing period and was considered treatment related, the other occurred during the follow-up 
period a nd was not considered treatment relat ed.One participant experienced 
2
non-treatment -related SAEs, 1 of which occurred in the follow -up period and the other 
occurred outside of the study  reporting period.
In C3421002, there were isolated values for labora tory tests, vital signs and ECG inter vals 
outside of the reference ranges; however, no clear adverse trends were apparent in these 
parameters.  As has been reported for marketed GLP -1R agonists11increases in heart rate 
were observed, with mean incr eases ranging from 5 to 15 beats per minute (bpm) across 
doses administered, and with most heart rate values within the normal range.   
[IP_ADDRESS]. Clinical Pharmacokine tics
The clinical PK of PF -[ADDRESS_207729] been evaluated in 
3complete d studies: C3421001, C3421002 and C3421003.  The results of these completed 
studies are summarized in the PF-[ADDRESS_207730] dose.  Mean t ½values ranged from 4.3 to 6.1 hours.  
Plasma exposure, as ass
essed by  [CONTACT_2715] -normalized geometric mean AUC infand C maxvalues, 
appeared to increase in a dose propor tional manner across the 3 mg to 300 mg doses.  
Variability  in PF -06882961 exposure based on geometric percent coefficient of variation 
(%CV) ranged from 5 0% to 91% for C maxand 28% to 60% for AUC inf across the [ADDRESS_207731] for the BID IR formulation treatments, with mean ratios based on dose normalized AUC
24(Rac) values ranging from 1.203 ‑2.009.  Day 28 plasma exposure as 
measured by [CONTACT_107074] 24values appeared to increase in an approximate dose 
proportional manner across all IR treatments. Urinary recovery of PF-06882961 was low, with <0.1% of the dose recovered unchanged in urine on Day 28. Mean t
½values on Day 28 
across all treatments ranged between 4.681 to 8.090 hours, and no apparent trends were observed across various treatments, regimens, or doses administered. Inter-participant variability for PF-06882961 exposure was based on geometric mean was 31%-87% for AUC
24and 32%-94% for C maxand on Day 28 across all treatments and cohorts. 
2.3. Benefit/Risk Assessment
A single dose of PF-[ADDRESS_207732] of varying degrees of renal impairment on the PK of PF-06882961.  Results from this study will be used in conjunction with collective safety, efficacy, and PK/PD data from other PF-[ADDRESS_207733] heart rate values within the normal range. Based on current Phase 1 data with PF-06882961, a 20 mg dose is anticipated to be well tolerated, even if plasma concentrations are higher with renal impairment.  
Considering all available clinical and nonclinical data, the benefit-risk profile of 
PF-06882961 supports continued clinical development in patients with T2DM.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-06882961 may be found in the IB which is the single reference safety document (SRSD) for this study. CCICCI
PF-[ADDRESS_207734] ives Endpoints
Prim ary: Prim ary: 
To compare the PKof PF -06882961 follow ing 
administration of a single oral dose in adult 
participants with T2DM and varying degrees of 
renal impairment relative to T2DM participants 
without renal impairment.Plasma: C max, AUC inf, AUC last, fu,as data permit .
Secondary: Secondar y: 
To compare additional PK parameters of 
PF-06882961 follow ing adm inistration of a 
single oral dose in adult participants with 
T2DM and varying degrees of renal impairment 
relative to T2DM participants without renal 
impairm ent.Plasma: Cmax,u,AUC inf,u, AUC last,u, CL/F, CL u/F,
Vz/F, V z,u/F, Tmax, t1/2, as data permit .
To evaluate the safety and tolerability of a 
single oral dose of PF -06882961 in T2DM
participants with varying degrees of renal
impairm entand in participants with normal 
renal function .Incidence and severity of treatment -emergent 
AEs, clinical laboratory abnormalities, vital signs 
(blood pressure and pulse rate) , ECG parameters 
(heart rate, QT, QTcF, PR and QRS intervals) .
Tert iary/Exploratory: Tertiary/Exploratory: 
To compare urine PK param eters of 
PF-06882961 follow ing adm inistration of a 
single oral dose in adult participants with 
T2DM and varying degrees of renal impairment 
relative to T2DM participants without renal 
impairment.Urine: CL r, Ae 24, Ae 24%.
To compare the PKof PF -06882961 follow ing 
administration of a single oral dose in adult 
participants with T2DM and normal renal 
function relative to healthy participants with 
norm al renal function.Plasma: C max, Tmax, AUC inf, AUC last, CL/F, V z/F, 
t1/2, fu,as data permit ;
Urine: CL r, Ae 24, Ae 24%.
To explore the relationship of markers of innate 
OATP activity in adult participants with T2DM 
and varying degrees of renal impairment 
relative to participants with norma l renal 
function .CP-I concentration .
To enable exploratory research through 
collection of banked biospecimens, unless 
prohibited by [CONTACT_168038].Potential results from exploratory analysis of 
banked biospecimens (these results may or may 
not be generated in the context of the present 
study).

PF-[ADDRESS_207735] of 
varying degrees of renal impairment on the PK, safety and tolerability of PF-06882961 after a single oral dose of 20 mg administered in a fed state ( Section 5.3.1 ).
Approximately 40 participants will be enrolled in the study. Refer to Table 1 below for 
details of study groups. Due to the potential difficulty in recruiting T2DM patients with estimated glomerular filtration rate (eGFR) <30 mL/min, the number of participants to be enrolled in this group is flexible (6 to 8 participants).
This study will permit enrollment of 2-[ADDRESS_207736] the clearance 
of PF-06882961 and therefore the dialysis clearance of PF-06882961 will not be characterized in this study.  Thus, Day 1 (per the SoA) will occur in dialysis patients on a day 
in which dialysis is notadministered.
Table 1. Study Groups
Group Disease State Renal Impairment No. of 
ParticipantseGFRa
(mL/min)
1 None (healthy) None (Normal Renal 
Function)8 ≥90
2 T2DM None (Normal Renal 
Function)8 ≥90
3 T2DM Mild 8 60-89
4 T2DM Moderate 8 30-59
5 T2DM Severe 6-8b<30
a. Estimate of eGFR based on the SCr-based CKD-Epi [INVESTIGATOR_10908].  The eGFR will be multiplied by [CONTACT_20908]’s 
ratio of BSA/1.73 to obtain the BSA-unnormalized eGFR value.  The average of the 2 unnormalized eGFR valuesfrom S1 and S2 will be used for study enrollment and group placement.  Note: participants on dialysis will be placed 
in Group [ADDRESS_207737] stable renal function to enter the study, defined as ≤25% difference between 2 measurements of BSA-unnormalized 
eGFR obtained from the 2 screening visits, S1 and S2 as listed in the SoA.
As indicated in Table 1, the estimate of eGFR will be based on the SCr-based CKD-Epi 
[INVESTIGATOR_10908]:
15CCI
CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 22eGFR (mL/min/1.73m2) = 141 × min ( SCr /κ, 1)α× max( SCr /κ, 1)-1.209× 0.993Age× 
1.018 [if female] × 1.159 [if Black ].
where: 
SCris serum creatinine in mg/dL (based on the standardized assay );
κ is 0.7 for females and 0.9 for males ;
  is -0.329 for females and -0.411 for males ;
Min indicate s the minimum of SCr/κ or 1;
Max indicates the maximum of SCr /κ or 1 ;
Age is in y ears.
The eGFR value will be multiplied by  [CONTACT_20908]’s ratio of BSA/1.73 to obtain the 
BSA -unnormalized eGFR value as shown below:
eGFR (mL/min) = eGFR (mL /min/1.73m2) * [BSA (m2) / 1.73] .
The BSA of an individual will be calculated using the following equation:16
BSA (m2) = [Weight(kg)0.425× Height(cm)0.725] × 0.007184
Participant s with T2DM and varying degrees of renal im pairment (Groups 3 -5) will be 
recruited and enrolled first.  An average value for age and weight for the se groups will be 
determined and participants in Group s 1-2 will be recruited to match the average 
demographics (at a minimum, age and weight ,and as mu
ch as practicall y possible gender) 
across the pooled Groups 3-5.  Recruitment for participants in Groups 1- 2 may  start when 
approximately  75% of total participant s across Groups 3-5 (ie, approximately  17-18 ) have 
been dosed.  
Approval from the sponsor must be garnered before proceeding with dosing 
participants in Groups [ADDRESS_207738] 
that is currently being investigated as chronic therapy to improve glycemic control in adult participants with T2DM.  Chronic kidney disease (CKD) occurs in 20-40% of patients with diabetes and may be present at the time of diagnosis of T2DM.
[ADDRESS_207739] drug metabolism and transport in other organs (such as the liver), which may lead to clinically relevant changes in non-renal clearance (where OATP substrates may be affected).
18-20  Based on this, and since patients with T2DM may 
experience varying stages of CKD, a full-range study design including participants with no, mild, moderate and severe renal impairment (including participants requiring dialysis) will be conducted.  Consistent with the recommendation in the draft FDA Guidance for Industry “Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labelling”
21that the participants should be representative of a 
typi[INVESTIGATOR_177247], T2DM participants will be the primary population.  Healthy participants with normal renal function will be enrolled to enable comparison of PK parameters between the age, weight, and gender of healthy participants, T2DM participantswith varying degrees of renal impairment, and T2DM participants with normal renal function.  
 Therefore, to compare exposures directly in 
this study, both T2DM and healthy participants with normal renal function are included.  Renal impairment classification will be based on the eGFR according to the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI) equation which has been used in renal outcome studies.
22,23,[ADDRESS_207740] a t ½of approximately 4-8 hours, 
plasma sampling up to 48 hours will be collected.  Since PF-06882961 is highly protein bound, to assess the in vivo protein binding of PF-06882961 with varying degrees of renal
impairment, the fraction unbound (fu) of PF-06882961 will be determined at approximately 
the expected T
maxin each participant.  To explore the relationship between OATP activity 
and CKD, the endogenous biomarker, coproporphyrin I (CP-I), will be measured prior to dosing. CP-I has been reported to be a potential marker of OATP activity. In this study, a single dose of PF-[ADDRESS_207741] the conditions for anticipated use of PF-06882961 in the target T2DM population.  Additionally, in study C3421001 in healthy participants, variability based on geometric %CV for C
maxwas 
lower following administration with a high-fat meal (23% in the fed state, compared to 91% in the fasted state). The adjusted geometric mean C
maxwas 57% lower (90% CI: 28%, 74%) 
in the fed state compared to the fasted state, while mean AUC infvalues were similar 
(approximately 12% lower in the fed state [90% CI: -5%, 26%]).CCI
CCI
CCI
PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 24While GLP-1R agonists typi[INVESTIGATOR_177248]-administered with anti-diabetic agents that can cause hypoglycemia (such as insulin or 
sulfonylureas), blood glucose concentrations will be monitored throughout the study via glucometer, and monitoring of symptomatic HAEs will be performed.  As is typi[INVESTIGATOR_177249], vital signs will be obtained in the seated position. In addition, COVID-[ADDRESS_207742] been incorporated to minimize the risks of COVID-19 related complications to participants and the study site personnel.
Both females of childbearing potential as well as those who are of non-childbearing potential 
will be enrolled given the availability of embryo fetal developmental (EFD) toxicity studies with PF-06882961.  However, as marketed GLP-1R agonists are listed as contraindicated in pregnancy, measures will be taken to limit the risk of pregnancy in the female population enrolled (see SoA and Section 10.4 ).
The potential risk of exposure to PF-06882961 in a sexual partner of a male participant in 
this study via ejaculate is low, and therefore no contraception (condom) use in male participants is warranted.  The calculated safety margin is ≥100-fold between the estimated 
partner exposure due to seminal transfer and the NOAEL for serious manifestations of developmental toxicity in nonclinical studies.  The safety margin of 100-fold is based on applying a 10-fold safety factor for interspecies extrapolation and a 10-fold safety factor for susceptible populations.
[ADDRESS_207743] single dose that is anticipated to be well tolerated (ie, 20 mg).  Since the exposure of PF-06882961 is approximately dose-proportional over the range of clinical doses (up to single dose of 300 mg and up to 120 mg BID), the results of this study can be extrapolated to understand the effect of renal impairment on the PK of PF-[ADDRESS_207744] completed the study  if he/she has completed all phases of 
the study  including the last scheduled procedure shown in the SoA.
The end of the study is defined as the date of thelast scheduled procedure shown in theSoA
for the last pa rticipant in the trial.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitme nt and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
5.1.1. Inclusion Criteria for All Parti cipants
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
1.Stabl e renal function (for participants not on dialysis) defined as ≤ 25% difference 
between 2measurements of eGFR (as calculated by  [CONTACT_177262] -identified central 
laboratory  using the CKD -EPI [INVESTIGATOR_10908])1obtained at Screening visits S1 and S2.  The 
average of t he 2 eGFR values obtained from S1 and S2 will be used for study  
enrollment and assignment to appropriate renal function group (see Table 1).Note : 
participants on dial ysis will be placed in Group 5 regardless of eGFR from S1 and S2
(S2 is optional for dialy sis participants only ).
Age and Sex:
2.Male and female p articipants must be ≥ 18 years of age, inclusive, at the time of 
signing the informed consent document (ICD) .
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1) and fe male 
(Section 10.4.2) participants.
Type of Par ticipant and Disease Characteristics:
3.Participants who are willing and able to compl y with all sc heduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures
, including 
the ability  to perform self- monitoring blood glucose at a frequency  deemed 
appropriate b y the investigator.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 26Weight:
4. B ody mass index (BMI) of ≥ 18.0 kg/m2and < 45.4 kg/m2; and a total body weight 
>50kg(110 lb).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1 (Section 
10.1), which includes compliance with the requirements and restrictions listed in the 
ICD
and in this protocol.
5.1.2. Additional Inclusion Criteria for Healthy Participants with Normal Renal 
Function (Group 1)
1.No clinically  relevant abnormalitie s identified by  a detailed medical history , full 
physical examination, including blood pressure (BP) and pulse rate measurement, 
standard 12- lead ECG and clinical laboratory  tests.
2.Normal renal function (mean eGFR ≥90mL/min) based on an average of measures 
from Screening visits S1 and S2.
3.Demographically  comparable to participants with impaired renal function:
a.A body  weight within ±15 kg of the mean bod y weight of the pooled renal 
impairment group s (Groups 3, 4,and 5), as provided by  [CONTACT_3211] ;
b.An age within ±10 years of the mean age of the pooled renal impairment group s
(Groups 3,4 and 5), as provided by  [CONTACT_3211] ;
c.Attempts will be made to ensure that the male to female distribution in Group 1 is 
comparable to tha t in the pooled renal impairment groups (Cohorts 3, 4, and 5) .
5.1.3. Additional Inclusion Criteria for T2DM Participants with Normal Renal 
Function (Group 2)
1.A prior diagnosis of T2DM with an HbA1c ≥6% and ≤10.5%, at Screening visit S1, 
confirmed b y a single rep eat, if deemed necessary .
2.Normal renal function (mean eGFR ≥90 mL /min) based on an average of measures 
from Screening visits S1 and S2.
3.See Appendix 8for details regarding prohibited prior/concomitant medications.
4.Demographically
 comparable to participant s with impaired renal function:
a.A body  weight within ±15 kg of the mean bod y weight of the pooled renal 
impairment groups (Groups 3, 4 ,and 5), as pr ovided by  [CONTACT_3211] ;

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 27b.An age within ±10 years of the mean age of the pooled renal impairment groups 
(Groups 3, 4,and 5), as provided by  [CONTACT_3211] ;
c.Attempts will be made to ensure that the male to female distribution in Group 2is 
comparable to that in the po
oled renal impairment groups (Cohorts 3, 4, and 5).
5.1.4. Additional Inclusion Criteria for T2DM Participants with Impaired Renal 
Function (Groups 3-5)
1.A prior diagnosis of T2DM with an HbA1c ≥6%and ≤10.5%, at Screening visit S1, 
confirmed b y a single repeat, i f deemed necessary .
2.Meet the eGFR criteria listed for Groups 3, 4 ,or 5(for participants not on dialy sis)in 
Table 1 based on an average of measures from Screening visits S1 and S2 .
3.Stable concomitant medications, as defined in Section 6.5, for the ma nagement of 
medical conditions relevant to an individual participant’s medical history . 
Participants receiving fluctuating concomitant medications/treatments may be 
considered, 
on a case-by-case basis with input from sponsor, if the underl ying 
disease is stable.
4.For Group [ADDRESS_207745] y:
Medical Conditions:
1.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or ac tive suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study participation or IPadministration or may  
interfere with the interpretation of study  results and, in the judgment of the 
investigator, would make the participant inappropriate for entry  into this study .
2.Any condition possibly  affecting drug absorption (eg, prior bariatric su rgery , 
gastrectom y, or an y area of intestinal resection, active inflammatory  bowel disease or 
pancreatic insufficiency ).NOTE :subjects who have undergone cholecystectomy  
and/or appendectom y are eligible for this study  so long as the surgery  occurred more
than 6 months prior to Screening;
3.Any malignancy  not considered cured (except basal cell carcinoma and squamous cell 
carcinoma of the skin); a participant is considered cured if there has been no evidence 
of cancer recurrence in the previous 5 years.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 284.Personal or famil y history of medullary  thyroid carcinoma (MTC) or multiple 
endocrine neoplasia s yndrome type 2 (MEN2), or participants with suspected MTC 
per the investigator’s judgement.
5.History  of chronic or acute pancreatitis within [ADDRESS_207746] the PK of 
PF-06882961.  See Section 6.5 for furth er information.
Prior/Concomitant Therapy:
13.See Appendix 8 (Section 10.8) for details regarding prohibited prior/concomitant 
medications.
Prior/Concurrent Clinical Study Experience:
14.Previous admi
nistration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_207747] dose of IPused in this 
study  (whichever is longer). 
15.Known prior participation in a trial involving PF -[ADDRESS_207748].
Diagnostic Assessments:
16.Screening standard 12-lead ECG that demonstrates a clinically  relevant abnormality  
that requires further diagnostic evaluation or intervention (e g, new, clinically  relevant 
arrhythmia, conduction disturbance, findings suggestive of ischemia).
  A potential 
participant whose pre-dose ECG (on Day  1, 0 hour) demonstrates a clinically  relevant 
abnormality  that requires further diagnostic evaluation or i ntervention will be
considered a screen failure.

PF-[ADDRESS_207749] (or other t ype of drug test in anuric participants on dialysis 
only).  
Note
:Participants who have been medicall y prescribed opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438] , 
benz odiazepi[INVESTIGATOR_177250] .Use of 
marijuana during inpatient stay  is prohibited. 
19. Participants with ANY of the follow ing abnormalities in clinical laboratory  tests at 
Screening, as assessed b y the study  specific central laboratory  and confirmed by  a 
single repeat test, if deemed necessary : 
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 
≥2 × upper limit of normal (ULN);
Total bilirubin level ≥1.5 × ULN; participants with a history  of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ ULN.
Fasting C -peptide <0 .8 ng/mL .
Fasting plasma glucose (FPG) >270 mg/dL (15 mmol/L) at screening (S1).
Other Exclusions:
20.History  of regular alcohol consumption exceeding 7 drinks/week for female 
participan tsor 14 drinks/week for male participants (1 drink = 5 ounces [150 mL ] of 
wine or 12 ounces [360 mL ] of beer or 1.5 ounces [45 mL ] of hard liquor) within 
6months before screening.
21.Blood donation (excluding plasma donations) of approximately  1 pi[INVESTIGATOR_11731] (500 m L) or 
more within [ADDRESS_207750] of 
the study . 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 305.2.2. Additional Exclusion Criteria for Healthy Participant s with Normal Renal 
Function (Group 1)
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurologic, or 
allergic disease (including clinically  relevant and sig nificant drug allergies, but 
excluding untreated, as ymptomatic, seasonal allergies at time of dosing).
2.Use of prescription or non- prescription drugs and dietary  and herbal supplements 
within 14 days or 5 half-lives (whic hever is longer) prior to the first dose of IP(Refer 
to Section 6.5 for additional details).  As an exception, ibuprofen or acetaminophen 
may be used at doses of ≤1g/day .  Limited use of non-pr escription medications that 
are not believed to affect participant safety  or the overall results of the study may  be 
permitted on a case -by-case basis following approval by  [CONTACT_456] .
3.Screening seated systolic blood pressure (SBP) >140 mmHg or diastolic blood 
pressure (DBP) >90mmHg, following at least [ADDRESS_207751].  If SBP is 
>140 mmHg or DBP >90mmHg, the BP should be repeated 2 more times and the 
average of the 3 BP values should be used to determine the participant’s eligibility .
4.
Participa nts with ANY of the following abnormalities in clinical laboratory  tests at 
Screening, as assessed b y the study  specific central laboratory  and confirmed by  a 
single repeat test, if deemed necessary :
HbA1c ≥6.0% at Screening visit S1 ;
FPG ≥126 mg/dL at scr eening (S1) ;
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 
≥1.5 × upper limit of normal (ULN).
5.2.3. Additional Exclusion Criteria for T2DM Participants with Normal Renal 
Function (Group 2 )
1.At Screening, seated s ystolic blood pressure (SBP) ≥160 mm Hg and/or diastolic 
blood pressure (DBP) ≥105mmHg after ≥5minute of seated rest, with a single repeat 
permitted to assess eligibility , if needed, at each of these 2 visits .
5.2.4. Additional Exclusion Criteria for T2DM Participants with Impaired Renal 
Functio n (Group s 3-5)only
1.At Screening, persistent severe, uncontrolled h ypertension; for example: seated
systolic blood pressure (SBP) ≥180 mmHg and/or diastolic blood pressure (DBP) 
≥105 mmHg after ≥5minute of seated rest, with a single repeat permitted to assess 
eligibility , if needed, at each of these 2 visits:

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 31For subjects with SBP ≥160mm Hg orDBP ≥[ADDRESS_207752] stable BP on Day 1(See 
Section 5.2.5).
2.For participants in Group 5 on Dialy sis onl y: Hemody namic 
instability  during or at 
the conclusion of dial ysis during the [ADDRESS_207753] satisfied all the following 
criteria:
In women of childbearing potential, urine pregnancy  test on Day  -1 is negative;
Cohort 1 and Cohort 2 only : Approval from the 
sponsor must be obtained before 
proceeding with dosing participants i n either Cohort 1 or Cohort 2;
Cohorts 2- 5 only : Participants must have measurement on Day  1 of SBP 
<160 mmHg and DBP <100 mm Hg;
A single repeat assessment is permitted, to confirm that the above criterion is met 
[and in such cases, the repeat assessment overrides initial results] .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
While inpatient, the meals consumed are expected to follow the restrictions outlined below:
Participants must abstain from all food and drink (except water) for at least 8 hours 
prior to scheduled safet y laboratory  and the predose PK evaluations. 
Dose administered in the f ed state on Day 1:
Water may  be consumed as desired (ad libitum).
After collection of predose safet y and PK samples on Day  1, participants should 
begin consumption of a standard breakfast approximately  30minutes prior to oral 
PF-[ADDRESS_207754].  

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 32Lunch will be provided approximat ely 4hours after oral dosing of PF -06882961. 
Dinner will be provided approximately  10hours after oral dosing of PF -06882961.  
An evening snack may  be permitted.
Noncaffeinated drinks (except grapefruit or grapefr uit related citrus fruit juices, see 
below) may  be consumed wit h meals and the evening snack.
Participants will refrain from consumin g red wine, grapefruit, or grapefruit related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_207755] 
dose of IPuntil collection of the final PK blood sample.  
While participants are confined, their total daily nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein.  The dail y caloric intake 
per participant should not exceed approximately  3200 k cal.
5.3.2. Caffeine, Alcohol, and Tobacco
Caffeine containing products will be permitted d uring the stud y with the following 
restrictions: caffeine containing products may  not be consumed within 2
hours prior 
to measuring vital signs and ECGs.
Participant s will abstain from alcohol for [ADDRESS_207756] will be considered sourc e data and will not be 
required to be reported.
Tobacco and nicotine usemay be allowed according to CRU practices.  
Tobacco /nicotine use will not be permitted during frequent sampling procedures and
will not be perm itted within 2 hours prior to an y vital sign or ECG assessments.  
Tobacco /nicotine use will also not be permitted 2 hours before and 2 hours following 
any dose of IP.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight tra ining, 
calisthenics, aerobics) for at le ast48hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pace will be permitted.
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
a female participant has selected an appropriate method of contraception (see Appendix 4
Section 10.4.4) andwill confirm that the participant has been instructed in its consistent and 
correct use.  At time points indicated in the SoA, the investigator o r designee will inform the 
participant of the need to usehighl y effective contraception con sistentl y and correctly and 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 33document the conversation and the participant ’s affirmation in the participant ’s chart 
(participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception) .  In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  entered in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participa nts to meet the 
Consolidated Standards of Repor ting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities.  Minimal information includes demography , 
screen failure details, eligibility  criteria, and any  SAE.
A parti cipant who qualified for this study  but did not enroll within the protocol prescribed 
screening period may
 be re -screened with approval from the sponsor.  All screening 
procedures must be repeated, and the participant assigned a new 8- digit study  specific subjec t 
identification (SSI D) number.
Individua ls who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened.  
6.STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed produ ct(s), 
placebo, or medical device(s) intended t o be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term investigational product (IP) m
ay be used 
synony mously  with study  intervention.
6.1.Study Interv ention Administered
For this study , the IPi[INVESTIGATOR_177251]-06882961.
PF-06882961 will be supplied by  [CONTACT_177263] 10 mg tablets in bulk along with individual dosing 
containers, as necessary , for unit dosing.
6.1.1. Administration
Participants will receive IPat approximately  0800 hours (plus or minus 2 hours).  Details on
meals and dietary  requirements and activity restrictions on the day  of dosing (Day 1) are 
given in Section 5.3 .
Investigator site personnel will administer IPwith ambient temperature water to a total 
volume of approximately 240 mL. Participants will swallow the IPwhole, and will not 
manipulate or chew the IPprior to swallowing.  

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 346.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention , as 
applicable for temperature -monitored shipments . 
2.Only  participants enrolled in the stu dy may  receive study  intervention and only  
authorized sit e staff may  supply  or administer study  intervention.   All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited t o the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature si nce previousl y documented for all 
site storage locations upon return to business
.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records). All study  
intervention swill be accounted for using a nIPaccountability  form/record.   
4. Further guidance and information for the final disposition of unused study  
interventions are prov ided in the IP manual.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_177264]. 
6.Study  interventions should be stored in their original cont ainers and in accordance 
with the labels. 
7.Deviations from the storage requirements, including an y actions taken, must be 
documented and reported to [COMPANY_007] on discovery
.  The site should activel y pursue 
options for re turning the study  intervention to the s torage conditions described in the 
labeling, as soon as possible.   Once an excursion is identified, the study  intervention
must be quarantined and not used until [COMPANY_007] provides permission to use the study  
interventio n.  It will not be considered a protoco
l deviation if [COMPANY_007] approves the use 
of the study  intervention after the temperature excursion. Use of the stud y 
intervention prior to [COMPANY_007] approval will be considered a protocol deviation. Specific 
details rega rding the definition of an excursion an d information the site should report 
for each excursion will be provided to the site in the IP manual.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 358.The sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site). If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by  [CONTACT_4618], and all destruction must be adequat ely 
documented.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the IPready for administration or dispensing to the participant by [CONTACT_3436].  Dispensing 
is defined as the provision of IP, concomitant treatments, and accompany ing information by  
[CONTACT_22806](s) to a healthcare provider, participant in accordance with this 
protocol.  L ocal health authority  regulations or investigat or site guidelines may  use 
alternative terms for these activities.
Tablets will be prepared at the CRU in the individual dosing containers b y 2operators, 1 of 
whom is an appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist).  
The tablets will be provided in unit dose containers and labeled in accordance with [COMPANY_007] 
regulations and the clinical site’s labeling requirements. 
6.3.Measures t o Minimize Bias: Randomization and Blin ding
6.3.1. Allocation to Investigational Product
This is a non-randomized, open -label study . The investigator’s knowledge of the treatment 
should not influence the decision to enroll a particular participant or affect the order in which 
participants are enrolle d.
The investigator will assign participant numbers to the participants as they  are screened for 
the study . The first [ADDRESS_207757] each participants’ unique numb er assigned in chronological 
order of whe n informed consent is obtained.
6.4. Study Intervention Compliance
IPwill be administered under the supervision of investigator site personnel.  The oral cavity  
of each participant will be examined following dosing to e nsure the IPwas taken.
6.5. Concomitant Therapy
Health y participants will abstain from all concomitant medications, except for the treatment 
of AEs , as described in Section 5.2.[ADDRESS_207758] 
prandial glucose readings at similar levels that are achieved at home and based on the 
calories consumed while confined in the CRU.  
Phosphate binders, antacids, and bile ac id binding resins (eg, cholesty ramine, colestipol) 
must not be administered within [ADDRESS_207759] the sponsor should there be question s as to whether a medication is 
permitted or prohibited.
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the AEs observed with PF-06882961.  Standard medical 
supportive care must be provided to manage the AEs, including administration of 
carboh ydrates to treat HAEs ( see Section 8.2.6).
6.6.
Dose Modification
Dose modification of PF -06882961 is not allowed.
6.7.Intervention 
After the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Not applicable as this is a single dose study.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 377.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  termination visit applies only  to participant s who received IPand then are 
prematurel y withdrawn from the study.  Participants should be questioned regarding their 
reason for withdrawal.   
The participant will be permanentl y discontinued both from the study intervention and from 
the study  at that time.  If a part icipant withdraws from the study , he/she may  request 
destruction of an y remaining samples taken and not tested, and t he investigator must 
document an y such requests in the site study  records and notify  the sponsor accordingl y.
If the particip ant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponso r may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserv ed.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the st udy 
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specif ically withdraws consent for any further contact 
[CONTACT_78258].  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_17062], as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital status (whether the participant is alive or dead) is being measured, publicly  

PF-[ADDRESS_207760] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_4538] r eschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule an d ascertain whether or not the participant wishes to and/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -
up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 teleph one 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalen t methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachabl e, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole ishandled as part of Appendix 1 .
8.STUDY ASSESSMENTS AND PROCEDURES
Participant s will be screened within 28 days prior to administration of the IPto confirm that 
they meet the study  population criteria for the study .  The investigator (or an appropriate 
delegate at the investigator site) must obtain a signed and dated ICDbefore performing any 
study -specific procedures.
  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immedia tely upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.

PF-[ADDRESS_207761] information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participant s in this study  is approximately  
90mL.  The actual collectio n times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 60 consecutive 
days.
To prepare f or study  participation, participant s will be instructed on the information in the 
Lifesty le Considerations andConcomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not Applicable .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and partic ipant -reported symptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 

PF-[ADDRESS_207762] also remove the contents of their pockets and remain 
still during measurement of weight. 
8.2.2. Vital Signs
Vital signs (s ystolic BP, diastolic BP, temperature and pulse rate) will occur as specified in 
the 
SoA. Seated BP will be meas ured with the participant ’s arm supported at the level of the 
heart and recorded to the nearest mmHg after approximately  5minutes of rest.  The same 
arm (preferabl y the dominant arm) will be used throughout the stud y.  Participant s should be 
instructed no t to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds.  When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes t o collection times, of BP and pulse rate will be 
permitted, as necessary
, to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Temperature
Body tem perature will be measured at the timepoints listed in the SoA.  No eating, drinking, 
or smoking is allowed for [ADDRESS_207763] 10 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, aqualified individual at the investigator site will make 
comparisons to baseline measureme nts.  Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥30 msecfrom the baseline andis >450 msec ; or b) 
an absolute QTc Fvalue is ≥[ADDRESS_207764] hourly until QTc F
values from 2 succe ssive ECGs fall below the threshold value that triggered the repeat 
measurement.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 41If a postdose QTc Finterval remains ≥30msecfrom the baseline andis >450 msec; or b) an 
absolute QTcFvalue is ≥500 msecfor any  scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator), or QTc Fintervals get progressively  longer, the 
participant should undergo continuous ECG monitoring.  A cardiologist s hould be consulted 
if QTc Fintervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper le ad 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat measurements may  notbe necessary  if a 
qualified medical provider’s interpretat ion determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix [ADDRESS_207765] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not assoc iated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_207766] dose of stud y intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/basel ine within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix [ADDRESS_207767] be negative for partici pants to receive IP. 
8.2.5. Glucometer Monitoring of Glucose
Investigators will monitor fingerstick blood glucose ( FSBG )using glucometer measurements 
in participants with T2DM at the times specified in the Schedule of Activities. FSBG
measurements should be taken before breakfast while the participant is confined to the CRU. 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 42FSBG readings will be maintained at the sites in source documents, and only  the glucose 
results from the laboratory  will be re ported in the study  database.  
Specificall y, if an FSBG result is ≤70 mg/dL , a second FSBG should be obtained to confirm 
the gluc ose value, in addition to a venous sample that will be sent to the clinical laboratory  
for confirmation.  If the value from this second FSBG is also ≤70 mg/dL, the second value 
will be recorded as a h ypoglycemic AE.  FSBG will continue to be monitored unti l the 
glucose value returns to >70 mg/dL.  Samples may  be taken more frequently  if deemed 
necessary  by [CONTACT_093].  FSBG readings from a glucometer are permitted at any  time if 
the invest igator or participant notes sy mptoms of hypoglycemia.
8.2.6. Managemen t of Hypoglycemia
Any epi[INVESTIGATOR_177252].  For the definition of a 
hypoglycemic epi[INVESTIGATOR_95461] y categorization see Section [IP_ADDRESS] below.
For medical management of hy poglycemia, the investigator may  administer oral 
carboh ydrate, glucagon, or IV glucose according to his or her medical judgment.  At a 
minimum however, treatment or administration of a scheduled meal should be given if 
glucose falls <60 mg/dL for at least [ADDRESS_207768] bot hersome s ymptoms of hy poglycemia along with glucose values of ≤ 70mg/dL.
[IP_ADDRESS]. Definition and Severity of Categorization of H ypoglycemic Adverse Event 
(HAE)
Based on review of the participant on site glucose monitoring, as well as results reported b y 
the central laboratory ,the investigator must assess the glucose values as well as any  
symptoms documented.
HAE is defined as 1of the following:
1.Asymptomatic hypoglycemia: An event not accompanied by  [CONTACT_11017][INVESTIGATOR_107062] a plasma glucose value of ≤70 mg/dL (3.9 mmoL /L) using glucometer (or 
sponsor -identified central laboratory )
.
2.Documented symptomatic hypoglycemia: An event during which ty pi[INVESTIGATOR_177253] a glucose value of ≤70mg/dL (3.9 mmol/L ) using 
glucometer (or sponsor -identifie d central la boratory ) andthe clinical pi[INVESTIGATOR_177254], subcutaneous glucagon, or intravenous (IV) 
glucose .
3.Probable symptomatic hypoglycemia: An event during which sy mptoms of HAE 
are not accompanied b y a plasma glucose determinati on but was presumably  caused 
by a plasma glucose concentration of ≤70mg/dL (3.9 mmol/L), andthe clinical 
pi[INVESTIGATOR_177255], subcuta neous glucagon, or IV 
glucose.

PF-[ADDRESS_207769] be met:
1.The participant exhibits altered mental and/or ph ysical functioning that requires 
assistance from another person for recovery .
2. The participants exhibit at least 1 of the following neurological s ymptoms:
Memory  loss;
Confusion;
Uncontrolled be havior;
Irrational behavior;
Unusual difficulty  in awakening;
Suspected seizure;
Seizur e;
Loss of consciousness.
3.Either:
If blood glu cose was measured and was ≤
54mg/dL (2.7mmol/L) using 
glucometer (or central laboratory ); or
If blood glucose was not measured, the clinical manifestations were reversed by  
[CONTACT_177265], subcutaneous glu cagon, or intravenous glucose.
Events that do not meet all criteria abov e for severe HAE should be characterized as mild or 
moderate in severity .
Any epi[INVESTIGATOR_95466].
8.2.7. Management of Hyperglycemia
Hypergl ycemia is defined as the following:
Fasting plasma glucose ≥270 mg/dL (15.0 mmol/L) using gluco meter (or central 
laboratory ). 
The investigator should determine if the participant collected the samples after an adequate 
fasting period; and if the participant is foll owing recommended dietary  guidelines.  Proper 
dietary  and collect ionprocedures shoul d be reinforced with the participant.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 44Aparticipant with hy pergl ycemia should receive treatment at the discretion of the 
investigator (see Section 6.5).
8.2.8. Pregnancy Testing
Pregnancy  tests 
will be both urine and serum tests, and must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .  
Following a negative pregnancy  test result at screening (S1 and S2) , appropriate 
contraception must be commenced/continued and a second negative pregnancy  test result 
will be required prior the participant ’sreceiving the IP.  Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or whe n potential 
pregnancy
 is otherwise suspected).  Preg nancy  tests may  also be repeated if requested b y 
Institutional Review Boards (IRBs)/ethics committees (ECs) or if required by  [CONTACT_13125].  
8.2.9. COVID -[ADDRESS_207770] be negative for admission to the C RU. 
8.3.
Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the particip ant's legall y authorized representative).
The investigator and an y qualified designees ar e responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classific ation as an SAE or that caused the participant to discontinue the
study (see Section 7).
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollectin g AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participa ntprovides informed consent, 
which is obtained before the participant ’s partici pation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_207771] SAE Report Form.
Investigators are not obligated to activel y seek AE or SAE after the participant has concluded 
study  participation .  However, if the investigator learns of an y SAE, including a death, at an y 
time after a participant has completed th e stud y, and he/she considers the event to be 
reasonabl y related to the study  intervention, the investigator must promptl y report the SAE to 
[COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participan tduring the active collection period are reported to [COMPANY_007] 
Safety  on the CT SAE Report Form i mmediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will sub mit any  updat ed SAE 
data to the sponsor within 24 hours of it being available.
SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investig ator believes have at least a reasonable possibility  of being related to IPmust be 
reported to [COMPANY_007] Safet y.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection per iod, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_207772] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 46Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follo w-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel yfollow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabili zation, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirem ents for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are me t.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will c omply  with country -specific regulatory  requireme nts relating to safet y 
reporting to the regulatory  authorit y, Institutional Review Boards (IRB s)/ethics committees 
(ECs
), and investigators.
Investigator safety  reports must be prepared for S uspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]R s) according to local regulatory requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety  report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs) from the spo nsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate according to local requir ements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the IPunder study  during pregnancy  or breastfeeding and occupational exposure 
are reportable to [COMPANY_007] Safet y within 24 hours of investigator awareness.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure Dur ing Pregnancy
Details of all pregnancies in female participants and female partners of male participants will 
be co llected after the start of study  intervention and until [ADDRESS_207773] 
administration of I P.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedur es outlined in Appendix 4 .
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios 
of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created wh en a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or ma y not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pe rtain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not Applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not Applicable .
8.3.8. Adverse Events of Special Interest
Not Applicable .
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.

PF-[ADDRESS_207774] S AE Report 
Form to [COMPANY_007] Safety Within 24 
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an S AE
Medication errors include:
Medication errors involving participant exposure to the IP;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is ac companied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to [COMPANY_007] Safety  within [ADDRESS_207775] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of PF -06882961 greater than 120 mg within a 24- hour time period 
(
±2hours) will be considered an overdo se.
There is no specific antidote for overdose with PF- 06882961.  Treatment of overdose should 
consist of general supportive measures.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 49In the event of an overdose, the investigator should:
1.Contact [CONTACT_44686] m onitor within 24 hours .
2.Closely  monitor the pa rticipant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of study  intervention 
(whichever is longer).
3.Obtain a blood sample for PK anal ysis within 2days from the date of the last dose of 
study intervention if requeste d by [CONTACT_44686] m onitor (determined on a case -by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
5.Overdose is reportable to Safety  only when associated with a nSAE .
Decisio
ns regarding dose interruptions or modifications will be made by  [CONTACT_177266] m edical m onitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics 
8.5.1. Plasma for Analysis of PF -06882961
Blood samples of approximat ely 3mL, to provide a minimum of plasma volume 1mL, will 
be collected into appropriately  labeled tubes containing dipotassium 
ethylenediaminetetraacetic acid (K 2EDTA) for measurement of plasma concentrations of 
PF-06882961 as specified in the SoA.  Instructions for the collection and handling of 
biological samples will be provided in the lab oratory manual or by  [CONTACT_456]. The actual 
date and time (24 -hour clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time (eg, within 6 minutes of a 60 -minute sample) relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and data collection tool (eg, CRF).   Collection of samples more than 
10hours 
after dose administration that are obtained ≤1hour away from the nominal time 
relative to dosing will not be captured as a protocol deviation, as long as the exact time of the 
collection is noted on the source docu ment an d data collection tool (eg, CRF ). 
Samples will be used to evaluate the PK of PF-06882961 . Samples collected for anal yses of 
PF-06882961 plasma concentration may  also be used to evaluate safet y or efficacy  aspects 
related to concerns arising during or after the study , for metabolite identification and/or 
evaluation of the bioanalyt ical method, or for other internal exploratory  purposes.

PF-[ADDRESS_207776] 
operating procedures (SOPs).
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised. Any deviation from the specified sample handling 
procedure resulting in compromised sample integrity  will be considered a protocol deviation.
8.5.2. Plasma for Determination of PF -06882961 Unbound Fraction
During the study , a blood sample ( approximately  12mL) to provide sufficient plasma for 
unbound fraction determination will be collected into an appropriately  labeled tube 
contain ing K 2EDTA as defined in the 
SoA.
8.5.3. Urine for Analysis of PF -06882961
One aliquot of approximately  2mL urine sample is needed for the analysis of PF -06882961.  
Urine will be collected at times specified in the SoA (but no urine will be collected for anuric 
dialy sis participants) .  
Prior to dosing on Day  1, each participant 
must complete a forced void with an 
aliquot (approximately  10 mL ) from this urine (urine blank) labeled and stored froz en 
for measurement of drug concentrations, per detailed instructions offered in a 
laboratory  manual prior to the start of the study . 
Following dosing on Day 1, each void post dose will be collected and saved in a 
container and stored in refrigerated condi tions (ie, 2 -8°C) for the duration of the 
collection interval, as specified in the SoA. 
At the end of the collection interval, participant s must complete a forced void 
with this complete void included as part of the interval collection;
The urine container will be mixed thoroughly  and total volume plus weight of the 
urine collected during the in terval recorded .
Details regarding the processing, storage and shippi[INVESTIGATOR_177256] .  Samples collected for urine analy ses of PF -06882961 may  also be used to 
evaluate safet y or efficacy aspects related to concerns aris ing during or after the study , for 
metabolite identification and/or evaluation of the bioanaly tical method, or for other internal 

PF-[ADDRESS_207777] be documented and reported to the sponsor.  On a case by [CONTACT_413], the sponsor may make a determination as to whether sample integrity has been compromised.  Any sample deemed outside of established stability, or of questionable integrity, will be considered a protocol deviation.  Samples for analysis of PF-06882961 PK will be analyzed using validated analytical methods in compliance with [COMPANY_007] SOPs.
8.6. Pharmacodynamics
PD parameters are not evaluated in this study.
8.7. Pharmacogenomics
Pharmacogenomics (specified analysis) are not evaluated in this study.
8.8. Biomarkers
Collection of a sample for biomarker research is also part of this study.
8.8.1. Exploratory Biomarker for Measurement of CP-I
A blood sample (approximately 4 mL) to provide sufficient plasma will be collected as 
defined in the SoA.  This sample may be used for other exploratory biomarker studies, unless 
prohibited by [CONTACT_177267] (EC) decision.CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 528.9.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a statistical anal ysis plan (SAP), which will be 
maintained by  [CONTACT_456].  The SAP may  modify  what is outlined in the protocol where 
appropriate; however, any  major modifications of the primary  endp ointdefinitions or their 
analyses will also be ref lected in a protocol amendment.
9.1.Statistical Hypotheses
No formal statistical h ypothesis testing will be performed in this study .
9.2.Sample Size Determination
Approximately  8 participants will be enrolled into each of the 5 groups ( healthy  normal, 
T2DM normal, T2DM mild, T2DM moderate andT2DM severe). This is an estimation 
study  and the sample size is based on the recommendation from the EMA in “Guideline on 
the evaluation of the PK of medicinal products in p atients with decreased renal function”28
and is consistent with the draft FDA Guidance for Indu stry “Pharmacokinetics in Patients 
with I mpaired Renal F unction: Study  Design, Data Anal ysis, and Impact on Dosing an d 
Labelling” .21
A sample size of 8 participants per group will provide 90% confidence intervals (CIs) for the 
difference between groups of ±0.490 on the natural logarithm scale for AUC inf(or Cmax)with 
80% cove rage probability . The expected widths of the 90% CIs with 80% coverage 
probability  for the comparisons of each of the T2DM renal impaired groups (Groups 3, 4, 5)
to the T2DM normal group (Group 2) and the comparison of the T2DM normal group
(Group 2) to the healthy  normal g roup (Group 1) are shown in Table 2 for a range of possible 
effects.
Table 2. Expected Widths of the 90% CIs (with 80% Coverage Probability) for
Different Possible Estimated Effects
Estima ted Effect
(Test/Reference )AUC infor Cmax
Probable 90% CI Probable CI Width
75% (46%, 122%) 76%
100% (61%, 163%) 102%
150% (92%, 245%) 153%
200% (123%, 326%) 203%
400% (245%, 653%) 408%

PF-[ADDRESS_207778] deviation of 0.489 
(equivalent to a geometric coefficient of variation of 52%) for both log eAUC infand log eCmax
based on data from the first in human study  in healthy  volunteers (C3421001 )and 
preliminary  data from the multiple ascending dose study  in T2D M (C3421002) .
Participants who discontinue from the stud y before completing all assessments may  be 
replaced at the discretion of the investigator and sponsor.
9.3.Populations for Analysis
For purposes of analy sis, the following populations are defined:
Populat ion Description
Enrolled All participants who sign the ICD.
Evaluable All participants assigned to IP and who take at least [ADDRESS_207779] calculated.
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analy ses, and procedures for ac counting for 
missing, unused, and spurious data. This section is a summary  of the planned statistical 
analyses of the primary  and secondary  endpoints.
9.4.1. Efficacy Analyses
An efficacy  anal ysis is not applicable to this study . 
9.4.2. Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, ECGs, BP, 
pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s.  Any  clinical 
laborator y, ECG, BP, and pulse rateabnormalities of potential clinical concern will be 
described.  Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurol ogical examination in formation, as 
applicable, collected during the course of the study will be considered source data and will 
not be required to be reported, unless otherwise noted.  However, an y untoward findings 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 54identified on physical and/or neurologic al examinations condu cted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE.  
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be consider ed source data, and will not be required to be 
reported, unless otherwise noted.  Demographic data collected at screening will be reported.   
COVID -19 specific assessments data will be considered source data and will not be required 
to be reported.
[IP_ADDRESS]. Electroc ardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc Finterval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum postdose QTc Fvalues and maximum 
increases from baseline in the following categories will be tabulated by  [CONTACT_3148]: 
Safety QTc FAssessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
9.4.3. Other Analyses 
Pharmacogenomic (PGx) data will be collected and retained for future analy ses, but will not 
be anal yzed, specificall y, for this study . 
[IP_ADDRESS]. Pharmacokinetic Analyses
[IP_ADDRESS].1. Analysis Populations
The anal ysis populations are defined as in Section 9.3.
[IP_ADDRESS].2.
Derivation of Pharmacokinetic Parameters Prior to Analysis
[IP_ADDRESS].2.1. Plasma
The plasma PK parameters for PF -[ADDRESS_207780] quantifiable 
concentration (C last).Linear/Log trapezoidal method.
AUC inf* Area under the plasma conce ntration -time profile 
from time zero extrapolated to infinite time.AUC last+ (C last*/k el), where C last*is the 
predicted plasma concentration at the last 
quantifiable time point estim ated from the 
log-linear regression analysis.
Cmax Maximum observed concentration. Observed directly from data.
Tmax Time to maximum observed concentration . Observed directly from data as time of 
first occurrence.
t1/2* Term inal half -life. Log e(2)/k el,
where k elis the terminal phase rate 
constant calculated by a linear regression 
of the log -linear concentration -time 
curve. Only those data points judged to 
describe the terminal log -linear decline 
will be used in the regression.
CL/F* Apparent clearanc e. Dose/AUC inf.
Vz/F* Apparent volume of distribution. Dose/(AUC inf*kel).
fu Fraction of unbound drug in plasma. Cu/C (where Cu represents unbound 
concentration and C represents total 
concentration) .
AUC last,u Unbound area under the plasma concentratio n-
time profile from time zero to the time of the last 
quantifiable concentration .fu*AUC last.
AUC inf,u Unbound area under the plasma 
concentration -time profile from time zero 
extrapolated to infinite time .fu*AUC inf.
Cmax,u Maximum ob served concentratio n of unbound 
drug.fu*C max.
CL u/F Apparent clearance of unbound drug. Dose/(AUC inf,u).
Vz,u/F Apparent volume of distribution of unbound 
drug.Dose/(AUC inf,u*kel).
* as data permit . 
[IP_ADDRESS].2.2. Urine
The following urine PK parameters will be calculated for PF -06882961 ( Table 4):

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 56Table 4. Urine PK Parameters
Param eter Definition Method of Determ ination
Ae24 Total amount of unchanged drug excreted in the 
urine over 24 hours .Sum of amount excreted for each 
collectio n period.
Ae24% Total amount of unchanged drug excreted in the 
urine over 24 hours, expressed as percent of dose .100*(Ae 24/Dose) .
CL r Renal clearance . Ae24/AUC 24.
[IP_ADDRESS].3. Statistical Methods
Linear regression will be used to characterize the potential relation ship between appropriate 
PK parameters (CL /F,CL u/F and CL r) for PF -06882961 and renal function (eGFR). eGFR 
values obtained on Day  1 and only  participants from the T2DM groups (Groups 2 to 5) will 
be included in the regression analy sis.Estimates of the slope and intercept, together with 
their precision (90% CIs), and the coefficient of determination will be obtained from the 
model. The effect of covariates such as weight, gender, and age may  be explored, and details 
will be provided in the SAP.
A one -way anal ysis of variance (ANOVA) will be used to compare the natural log 
transformed AUC inf(if data perm it), AUC last, Cmax, fu, AUC inf,u(if data permit), AUC last,uand 
Cmax,u of PF -06882961 for each of the T2DM renal impairment groups (Test , Groups 3, 4, 5) 
to the T2DM normal renal function group (Reference , Group 2 ). Also, the T2DM normal 
renal function g roup (Test , Group 2) will be compared to the healthy  normal renal group 
(Reference , Group 1). The ANOVA model will include all groups ( ie,both T2DM an d 
healthy  participants from the 5 groups). Estimates of the adjusted mean differences ( Test-
Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean 
differences and 90% CI s for the differences will be exponentiated to provi de estimates of the 
ratio of adjusted geometric means (Test/Reference) and corresponding 90% CI s.If 
substantial differences in demographic characteristics between healthy (Group 1) , T2DM 
normal (Group 2) and T2DM renal impairment function participants (Groups 3, 4, 5) are 
observed, covariates such as weight , gender ,and age may  be explored.
The PK parameters for PF- 06882961 will also be summarized descriptively  by [CONTACT_177268] (healthy  vs. T2DM). Box and whisker plots for individua lPK
parameters (AUC inf, AUC last, Cmax, fu, AUC inf,u, AUC last,uand C max,u)will be constructed b y 
renal function group and population and overlaid with geometric means.
For summary  statistics and median or mean plots by  [CONTACT_31065], the nominal PK 
sampl ing time will be used. For individual participant plots by  [CONTACT_5586], the actua l PK sampling 
time will be used.
Plots of PK parameters (CL /F,CL u/F andCL r) for PF -06882961 versus renal function (eGFR
as obtained on Day 1) will be constructed. A regression li ne and 90% confidence region for 
the PK parameters and eGFR will be include d if appropriate. Vertical lines for the renal 
function group cut -off values will also be presented on the plots. Different sy mbols will be 
used to identify  participants from diff erent renal function groups.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 57Consistent with the draft FDA Guidance for Industry ,21,18relevant tables and figures may  be 
generated based on eGFR calculated using the C ockcroft -Gault or the Modification of Diet in 
Renal Disease (MDRD) formulas as described in the SAP.
9.5.Interim Analyses
No formal interim anal ysis will be conducted for this stud y.As this is an open-label stud y,
the sponsor may  conduct unblinded reviews of the data during the course of the study  for the 
purpose of safet y assessment, facili tating PK/PD modeling, and/or support ingclinical 
development. 
9.5.1. Data Monitoring Committee 
This study  will not use a D ata Monitoring C ommittee (DMC ).

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 5810. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organiza tions of Medical 
Sciences (CIOMS) International Ethical Guidelines ;
Applicable International Council for Harmonisation (I CH) Good Clinical Pra ctice 
(GCP) g uidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, I nvestigator’s B rochure ( IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by [CONTACT_177269] I RB/EC by  [CONTACT_20003] b y the IRB/EC 
before the study  is initia ted.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the fo llowing:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y find ings as required by  
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event o f any  prohibition or restriction imposed (ie, clinical hold) by  [CONTACT_78270] y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the IP, [COMPANY_007] 
should be informed immediatel y.

PF-[ADDRESS_207781], and 
of an y serious breaches of this pro tocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestig ators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate f inancial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 yearafter completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
partic ipant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their particip ation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statem ent of informed consent that 
meets the requirements of [ADDRESS_207782] (HIPAA) requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant or his or her le gally  authorized 
representative is fully  informed about the nature and objectives of the study , the shar ing of 
data related to the study ,and possible risks associated with participat ion, including the risks 
associated with the processing of the participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_177270] r authorized personnel appointed by  [CONTACT_456], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant or his or her le gally 
authorized representative is fully  informe d about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before t he participant wa s enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.

PF-[ADDRESS_207783] current version of the IC D(s) during their 
participation in th e study .
A cop y of the IC D(s) must be provided to the participant or the participant’s legall y 
authorized representative.
The I CDwill contain a separate section that addresses the use of remaining mandatory  
samples for optional explorator y research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory  research. Participants will be 
told that they  are free to refuse to participate and may  withdraw their consent at any  time and 
for an y reason during the storage period. A separate signature [CONTACT_22862] a 
participant's agreement to allow an y remaining specimens to be used for exploratory 
research. Participants who decline to participate in this optional research will not provide 
this sep
arate signature.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data w ill be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code. 
Any participant records or data sets that are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred. 
All other identifiable data 
transferred to the sponsor will be identified by  [CONTACT_20007], participant -specific code. The 
study  site will maintain a confidential list of participant s who participated in the study , 
linking each participant ’s numerical code to his or her actual identity . In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on 
www.clinica ltrials.gov (ClinicalTrials.go v), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, [COMPANY_007] reports study  results outside of the 
requirements of local laws/regulations p ursuant to its s tandard operating procedures (SOPs).

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 61In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the co untry  in 
which the study  was c onducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographica l location in which the study  is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary completion date 
(PCD) for studies in adult populations or within [ADDRESS_207784]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for stu dies in adult populations or w ithin 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) o n www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.   Clinical data, under Phase 1 of this 
policy ,includes clinical overviews, clinical summaries, C SRs, and appendices containing the 
protocol and protocol amendments, sample CRF s, and statistic al methods. Clinical data, 
under Phase 2 of this policy ,includes the publishing of individual participant data. Policy  
0070 applies to new marketing authorization applications submitted via the centraliz ed 
procedure since 01January 2015 and application s for line extensions and for new indications 
submitted via the centralized procedure since 01 July  2015.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 62Data Sharing
[COMPANY_007] provides researchers secure access to p atient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion .  Patient
-level data will be anon ymized in accordance with 
applicable privacy  laws and reg ulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will no t 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Qualit y Assurance
All participant data relating to the stud
y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are ac curate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit 
study -related monitoring, audits, IRB/EC review, and 
regulatory  agency inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details desc ribing strategy  (eg, risk-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical 
risk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monit oring techniques (central, remote, or on -site monitoring) ,are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 63Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
docume nts; that the safety  and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICD s, pertaining to the conduct of this study  must 
be retained by [CONTACT_1732] 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destr oyed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored secu rely for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator w ill cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any discrepancies that are identified 
between the stud y data and the participant's med ical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authori ties, the investigator will provide the sponsor or its 
agents with an opportunity to r eview and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.   Source documents are filed at the investigator site.
Data re ported on the CRF or entered in the electronic CRF ( eCRF )that are transcribed from 
source documents must be consistent with the source documents or the discrepancies mus t be 
explained . The investigator may
 need to request previous medical records or tran sfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the study  monitoring pl an (SMP).
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a study -siteclosure visit has been performed.

PF-[ADDRESS_207785] 
research organization ( CRO )if requested to do so by  [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
Study termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be p ublished or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after end of the study  (or 
study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any subsequent publications 
such as secondary  manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y
-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all pub
lications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites.   In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.   In this case, a coordinating investigator [INVESTIGATOR_159828] b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  [CONTACT_177271]. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 6510.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_78276] (SToD) 
system.
To facilitate access to appropriatel y qualified medical personnel on study -related medical 
questions or problems, participant s are provided with a con tact card.  The contact [CONTACT_95504], at a minimum, protocol and IPi[INVESTIGATOR_110245], participant numbers, contact [CONTACT_177272], and contact [CONTACT_4664] a contact [CONTACT_177273] a medical question or problem 
originating from another healthcare professional not involved in the participant ’s 
participation in the study .  The contact [CONTACT_177274]; however, it should be used onl y in the 
event that the established communication pathways between the investigator site and the 
study  team are not available.  I t is therefore intended to augm ent, but not replace, the 
established com munication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  For sites other than 
a [COMPANY_007] CRU, the contact [CONTACT_177275] d for use b y the participant directly , and if a 
participant calls that number, he or she will be directed back to the investigator site.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 6610.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory  results may be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_177276] ; or as derived 
from calcula ted values.  These additional tests woul d not require additional collection of 
blood.  Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  concerns.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 67Table 5. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN/urea 
Creatinine
eGFR
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
Magnesium
Phosphate
AST 
ALT
Total bilirubin
GGT
Alkaline phosphatase
Uric acid
Albumin
Total protein
Amylase
LipasepH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobili nogen
Urine bilirubin
MicroscopyaSerum and Urine 
Pregnancy test ( -hCG)d
COVID -[ADDRESS_207786]
At screen ingonly:
HbA1c
Serum FSHb
C-peptide
Urine drug screeningc
Additional Testse
AST, ALT (repeat)
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase (repeat)
Direct bilirubin
Indire ct bilirubin
Creatine kinase
GGT
PT/INR
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.At screening (S1) and in females only.
c.The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol (THC),
opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific). Participants 
may undergo random drug testing at the discretion of the investi gator. For a participant on dialysis who 
is anuric only, an alternative method (eg, sal iva) for drug testing may be used.
d.Serum and urine pregnancy testing for all w omen of childbearing potential (WOCBP) ; urine pregnancy
testing to be done on -site using kits provided by [CONTACT_3211] -identified central laboratory .For a participant 
on dialysis wh o is anuric only, an alternative method (eg, blood) for urine pregnancy testing may be 
used.
e.Additional testing only for the management of participants with elevated liver enzymes as outlined in 
Appendix 6.
Investiga tors must document their review of each laboratory  safet y report.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 68Any remaining serum/plasma from samples collected for clinical safet y laboratory 
measurements at baseline and at all times after dose administration may  be retained and 
stored for the duration of the study .  Upon completion of the study , these retained safet y 
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 
safet y findings.  These data will not be included in the Clinical Study Report (CSR).  
Samples 
to be used for this purpose will be shipped to either a [COMPANY_007]-approved Biospecimen 
Banking S ystem (BBS) facility  or other designated laboratory  and retained for up to 1 year 
following the completion of the study .

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 6910.3. Appendix 3: Adverse Events: Definitions and Pro cedures for Recording, 
Evaluating, Follow -up, and Repo rting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clini cally significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mpto ms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self
-harming in tent. Such overdoses should be r eported regardless of 
sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless j udged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 70the disease/disorder being studied, unless more severe than expected for the 
partic ipant’s condi tion.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start o f the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if se rious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definiti on of “ serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_155190] n of existing hospi[INVESTIGATOR_177257], hospi[INVESTIGATOR_19949] (usually 
involving at least an over night stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriat e in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi [INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_12191]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that d id not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabil ity means a substantial disruption of a person’s ability  to conduct 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 71normal life functions.
This definition is not intended to include experien ces of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza , and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial d isruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exerc ised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_177258]. These events 
should usually  be consi dered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
depen dency  or drug abuse.
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exp osed to a 
[COMPANY_007] product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are consider ed unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also 
considered for re porting as product defects, if appropriate.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
Thetable below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to [COMPANY_007] Safety .  These requirements are delineated for 3 ty pes of
events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the IPunder 
study  during pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AE s should be recorded using concise medical 

PF-[ADDRESS_207787] SAE 
Report Form to [COMPANY_007] 
Safety Wit hin 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the IPunder 
study  during pregnancy  
or breastfeeding, and 
occupat ional exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recordedAll (and exposure during 
pregnancy  [EDP ]
supplemental form for 
EDP)
Note: I nclude all SAEs 
associated with exposure 
during pregna ncy or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) re lated to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_177259] b y [COMPANY_007] Safety . In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_1093] m edical 
records before submission to [COMPANY_007] Safety .
The investigator will attempt to establis h a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will b e documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 73Mild: An event that is easily  tolerated by  [CONTACT_126727], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is a ssessed 
as severe should not be confused with a nSAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a re lationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as und erlying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or product 
information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in whic h an SAE has occurred and the investigato r has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when det ermining regulatory  

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 74reporting requir ements.
If the investigator does not know whether or not the IPcaused the event, then the 
event will be handled as “related to investigational product” for reporting purposes, 
as defined b y the sponsor .  In addition, if the investigator determines that an SAE is 
associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the CT SAE Report Form and in acc ordance with the SAE 
reporting requi rements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during participa tion in the study  or during a recognized 
follow -up period, the investigato r will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology . 
New or updated information will be recorded in the originally  completed CRF.
The invest igator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety willbe the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the elec tronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE f rom a study  participant or receives updated 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 75data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_177277] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages w ithin the designated reporting 
time frames.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 7610.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100- fold between the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in no nclinical studies.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to partic ipate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3);
OR
Is a WOCBP and usin
g a contraceptive method that is highly effective (with a failure 
rate of <1% per year), as described below , during the intervention period and for at 
least [ADDRESS_207788] dose of study  intervention ,which corresponds to the time 
needed to eliminat e any study intervention(s) .The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.
The investigator is responsible for review of medical history , menstrual history , and rece nt 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fe rtile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study intervention, ad ditional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 77For individu als with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categori es can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.   The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as age 60 yearsor older or no menses for 
12months with
out an alternative medical cause. 
A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormon ereplacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue the ir HRT during the study.   Otherwise, they  must 
discontinue HRT to allow confirmation of postmeno pausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD) .
3.Intrauterine hormone -releasing s ystem (IUS) .
4.Bilateral tubal occlusion .
5.Vasectomized partner .
Vasectomized partner is a highl y effective contraceptive method provided that th e 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not , an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 78Highly Effective Methods That Are User Dependent 
1.Combined (estrogen- and progestogen -containing) hormonal contraception associate d 
with inhibition of ovulation .
Oral;
Intravaginal;
Transdermal ;
Injectable .
2.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable .
3.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usua l 
lifesty le of the participant.
Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or hav ing been 
exposed (eg, because of treatment or environmental exposure) to the IP; or the female 
becomes or is found to be pregnant after discontinuing and/or being exposed to the 
IP;
An example of environmental exposure would be a case involving direct cont act 
with a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
IPprior to or around the time o f conception and/or is exposed during his partner’s 
pregnancy .

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 79If a participant or participant ’s partner becomes or is found to be pregnant during the 
participant ’s treatment with the IP, the investigator must report this information to [COMPANY_007] 
Safety  on th e CT SAE Report Form and an EDP supplemental form, regardless of whether an 
SAE has occurred.  In addition, the investigator must submit information regarding 
environmental exposure to a [COMPANY_007] product in a pregnant woman (eg, a participant reports 
that she is pregnant and has been exposed to a cy totoxic product by  [CONTACT_177278]) to 
[COMPANY_007] Safety  using the EDP supplemental form.  This must be done irrespective of whether 
an AE has occurred and within 24 hours of awareness of the exposure.  The info rmation 
submitted should include the anticipated date of delivery  (see below fo r information related 
to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown out come.  The investigator will follow the pregnancy  until 
completion (or until pr egnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the n eonate can be assessed at the time of birth.  In the event of a termination, th e 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unle ss 
preprocedure test findings are conclusive for a congenital anomal y and the f indings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fe tal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed a bortion;
Neonatal deaths that occur within [ADDRESS_207789] 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reporte d as 
SAEs when the investigator assesses the infant death as related or possibl y related to 
exposure to the IP. 
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06882961
Protocol C3421012Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 80CCI
CCI
PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 8110.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  
In some participant s, transaminase elevations are a harbinger of a 
more serious potential ou tcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participant s who experience a transaminase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (T Bili) elevations (>2 ×ULN) by  [CONTACT_74097].  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/AL T and TBili values will be elevated within the same lab oratory
sample).  In rare instances, by  [CONTACT_177279], AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  The refore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury  
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laborat ory abnormalities should be evaluated further as pote ntial DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values ar e used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the n ormal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_207790]/AL T and TBili separated by  [CONTACT_726] a few we eks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be eval uated as soon as possible, 
preferabl y within [ADDRESS_207791] and AL T and TBili for su spected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to de termine etiology .  A detailed history , including rele vant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testi ng for acute 
hepatitis A, B, C, D, and E infe ction and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laborator y criteria of AST/AL T and 
TBili elevation def ined above should be considered potential DILI (Hy
’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been r eceived and have excluded an alternative etio logy.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 8310.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AE s
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent premature ventricular complexes (PVCs), triplets , orshort intervals 
(<30 seconds) of consecutive ventricular complexes .
ECG Findings T hat May Q ualify as SAE s
QTcF prolongation >500 ms ec.
New ST -Tchanges suggestive of myocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New-onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥ 3.0 seconds or an y escape rate <40 bpm, o r with an escape rhythm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_207792] 5 seconds or longer. 
Atrial f lutter or fibrillatio n, with rapid ventricular response rate: r apid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute).
Ventricular r hythms >30 seconds’ duration, including idiovent ricular rh ythm 
(rate <40 bpm), accelerated idioventricular rh ythm (40< x <100) ,and 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 84monomorphic/poly morphic ventricular tach ycardia >100 bpm (such as torsades de 
pointes) .
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as S AEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemake r placement .
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 8510.8. Appendix 8: Prohibited Prior/Concomitant Medications
The following medications are prohibited until the follow
-up visit (ie, 28- [ADDRESS_207793] dose) , unless stated otherwise.  If a participant receives a prohibited medication, the 
investigator should contact [CONTACT_177280] m edical m onitor to determine if 
the partic ipant should be included in the study .
Drug Classes and/or Drugs Timeframe of Restriction 
GLP -1R agonists . 90 days prior to Screening 
Visit S1
DPP-4 inhibitors , pram lintide, repaglinide. Screening Visit (S1) to 
Follow  Up visit
Systemic glucocorticoids such as prednisone, dexamethasone, triamcinolone, 
budesonide, betamethasone.  Note: As an exception, steroid -containing 
inhalers, nasal sprays and topi[INVESTIGATOR_95471].  Screening Visit (S1) to 
Follow  Up visit
Immunosuppressants such as cyclosporine and tacrolimus. Screening Visit (S1) to 
Follow  Up visit
Rosuvastatin.  Note: Other statins are permitted. Day 1 (day of dosing)
Sulfasalazine (sensitive BCRP substrate) Day 1 (day of dosing)
Use of chronic agents which are clinically significant OATP inhibitors 
(eg,cyclosporine, gemfibrozil, rifampin).Screening Visit (S1) o 
Follow  Up visit
Use of chronic agents which are potent inducers of CYP3A (eg, rifampin ,
phenytoin, car bamazepi[INVESTIGATOR_050], phenobarbital ).Screening Visit (S1) to 
Follow  Up visit
Use of potent CYP3A4 inhibitors (eg, ritonavir, indinavir, itraconazole, 
clarithromycin) .Screening Visit (S1) to 
Follow  Up visit
Use of moderate CYP3A4 inducers (eg, efavirenz, lopi[INVESTIGATOR_5326] r, elagolix) . Screening Visit (S1) to 
Follow  Up visit
Use of moderate CYP3A4 inhibitors (eg, diltiazem, verapamil, erythromycin , 
fluconazole ).Screening Visit (S1) to 
Follow  Up visit

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 8610.9. Appendix 9: Proposed Chronology of Procedures
Forthe procedures descr ibed below, where multiple procedures are scheduled at the same 
timepoint(s) relativ e to dosing, the following chronology  of events should be adhered to:
12-lead ECG: obtain prior to vital signs assessment, blood samples, and prior to 
dosing (except for po st-dose collection) (see Section 8.2.3 ); 
Vital Signs (BP, PR , temperature): obtain after 12 -lead ECG collection but prior to 
obtaining blood samples and prior to dosing (except for post- dose collection) (see 
Section 8.2.2); 
Fasting blood samples [for safet y (see Section 8.2.7 ), PK (see Section 8.5), 
exploratory  biomarkers (see 
Section 8.8) and banked biospecimens (see 
Section 8.7.1)]: after assessment of 12 -lead ECG and vital signs but prior to dosing; 
For the random, post dose PK blood collection to occur approximately  [ADDRESS_207794] dose (see 
Section 8.5 ): if collection time coincides with time of a meal/snack, 
these blood samples should be collected just prior to the meal/snack;
Other pre -dose procedures: obtain s ample/perform procedure as close as possible to 
the scheduled time, but may  be obtained before or after blood sample collection(s); 
Dosing: must occur with the morning meal; and where applicable, after an y pre -dose 
blood sample collection(s). 

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 8710.10. A ppendix 10: Abbreviations
The following is a list of abbreviations that may  be used in 
the protocol. 
Term
Abs absolute
AE adverse event
Ae24 total amount of unchanged drug excreted in the urine over 24 hours
Ae24% total amount of unchanged drug excreted in the urine over [ADDRESS_207795] quantifiable concentration (C last).
AUC last,u unbound area under the plasma concentration -time profile from time 
zero to the time of the last quantifiable concentration
AV Atrioventricular
BBS Biospecimen Banking System
BCRP breast cancer resistance protein
-hCG beta-human chorionic gonadotropin
BID twice dail y
BMI body  mass index
BP blood pressure
bpm beats per minute
BSA body  surface area
BUN blood urea nitrogen
cAMP cyclic adenosine monophosphate
CFB change from baseline
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney  disease
CKD -EPI [INVESTIGATOR_177260] u/F apparent clearance of unbound drug after oral administration
CL r renal clearance

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 88Term
CL/F apparent clearance
Cmax maximum observed concentration
Cmax,u maximum observed concentration of unbound drug
CO 2 carbon dioxide (bicarbonate)
CONSORT Cons olidated Standards of Reporting Trials
COVID -[ADDRESS_207796] clinical trial
%CV percent coefficient o f variation
CYP cytochrome P450
DBP diastolic blood pressure
DPP Dipeptidy l Peptidase
DDI drug-drug interactions
DILI drug-induced liver injury
DMC Data Monitoring Committee
DNA deox yribonucleic acid
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDP exposure during pregnancy
EFD embry o fetal development al
EMA European Medicines Agency
eGFR estimated glomerular filtration rate
ET early termination
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FSBG fingerstick blood glucose
FPG fasting plasma glucose
FSH follicle -stimulating hormone
fu fraction of unbound drug in plasma
FU follow up
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GLP-[ADDRESS_207797]
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmoni sation
IND investigational new drug application
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IR immediate release
IRB Institution al Review Board
IUD intrauterine device
IUS intrauterine hormone -releasing s ystem
IV intravenous
IVGTT intravenous glucose tolerance test
K2EDTA dipotassium ethy lenediaminetetraacetic acid
LFT liver function test
Loge natural logarithm
MATE multidr ug and toxin extrusion protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDRD Modification of Diet in Renal Disease
MDR1 multidrug resistance mutation
MEN2 multiple endocrine neoplasia syndrome t ype2
mg/kg milligrams per kilogram
msec millisecond
MTC medullary  thyroid carcinoma
N/A not applicable
NOAEL no-observed -adverse -effect level
OATP organic anion transporting pol ypeptides
OCT2 organic cation transporter 2
PCD primary  comp letion date
PD pharmacod ynamic(s)
PE physical examination
PGx pharmacogenomic(s)
PK pharmacokinetic(s)
PR ECG parameter /interval
PT prothrombin time
PVC premature v entricular contraction/complex
QRS ECG parameter /interval

PF-[ADDRESS_207798]
QTcF QTc corrected using Fridericia’s formula
qual qualitative
Rac accumulation ratio
RBC red blood cell
RNA ribonucleic acid
S1 screening visit [ADDRESS_207799] slow titration
SToD study  team on demand
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t1/2 terminal phase half-life
TBili total bilirubin
TEAE treatment -emergent adverse event
THC tetrah ydrocannabino l
Tmax time to maximum observed concentration
T2DM type 2 diabetes me llitus
UGT uridine 5' -diphospho -glucuronos yltransferase
ULN upper limit of normal
US [LOCATION_002]
Vz/F apparent volume of distribution 
Vz, u/F Unbound Vz/F
WBC white blood cell
WOCBP woman of childbearing potential

PF-[ADDRESS_207800] JJ, Knuhtsen S, et al. Glucagon- like peptides GLP -1 and GLP -2, 
predicted products of the glucagon gene, are secreted separatel y from pig small intestine 
but not pancreas. Endocrinology . 1986;119(4):1467 - 75.
2. Krey mann B, Williams G, Ghatei MA, et al. Glucagon - like peptide-1 7 -36: a 
physiological incretin in man. Lancet .1987;2(8571):1300-4.
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon -like peptide 1 inhibition of 
gastric empt ying outwe ighs its insulinotropic effects in healthy  humans. Am J P hysiol.
1997;273(5):E981
-8.
4. Flint A, Raben A, Astrup A, et al. Glucagon -like peptide [ADDRESS_207801] .1998;101(3):515 -20.
5. Hu FB. Globalization of diabetes : the role of diet, lifesty le and genes. Diab etes Care .
2011;34:1249-57.
6. IDF Diabetes Atlas ; 9thEdition 2019. Available from : http://www.idf.org/diabetesatlas . 
Accessed: 
30 Jul 2020 04 Feb 2019.
7. Menke A, Casagrande S, Geiss L , et al. Prevalence of and trends in diabetes among 
adults in the [LOCATION_002], 1988- 2012. JAMA . 2015;314(10):1021-9.
8. DeFronzo RA. From 
thetriumvirate to the ominous octet: a new paradigm for the 
treatment of t ype 2 diabetes mellitus. Diabetes .2009;58:773 -95.
9. Stratton I M,Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular 
and microvascular complications of ty pe 2 diabete s ([LOCATION_006]PDS 35): prospective 
observational study . BMJ .2000;321:405-12.
10. Drucker, DJ .The ascending GLP -1 road from clinical safety  to redu ction of 
cardiovascular complications. Diabetes . 2018; 67(9 ):1710 - 19. 
11. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon
-like peptide -1 
receptor agonists on heart rate. Cardiovasc Dia betol. 2017;16(1): 6.
12. Victoza [package insert ]. Plainsb oro, NJ: Novo Nordisk I nc; 2016 .
13.
Ozempic [ package insert ]. Plainsboro, NJ: Novo Nordisk Inc; 2017.
14. Trulicity  [package Insert ]. Indianapolis, IN: Eli L illy and Co; 2017. 
15. Levey  AS, Stevens LA, Schmid CH, et al.A new equation to estimate glomerular 
filtration rate . Ann Intern Med. 2009; 50
(9):604-12.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 9216. Wang Y, Moss J, Thisted R. Predictors of bod y surface area. J Clin Anesth. 199 2; 
4(1):4-10.
17. American Diabetes Association. Standards of medical care in diabetes .Diabetes Care. 
2004;42Suppl 1): S15-S135 .
18. Nolin, T D, Naud, J , Leblond, FA ,et al. Emerging evidence of the impact of kidney  
disease on drug metabolism and transport. Clin Pharmacol Ther. 2008; 83(6):898–903.
19. Yeung, C K
, Shen, DD , Thummel, K E,et al.. Effects of chronic kidney  disease and 
uremia on h epatic drug metabolism and transport. Kidney  Int. 2014; 85(3): 522–8.
20. Tan, M
L, Yoshida, K, Zhao, P, et al. Effect of chronic kidney  disease on nonrenal 
elimination pathway s: a sy stematic assessment of CYP 1A2, CYP2C8, CYP2C9, 
CYP2C19, and OATP. Clin Pharma col Ther . 2018; 103(5):854 -67.
21. US Food and Drug Administration. Guidance for i ndustry : pharmacokinetics in patients 
with impaired 
renal function -study  design, data analy sis , and impact on dosing and 
labeling . Available from: https://www.fda.gov/regulato ry-information/search- fda-
guidance -documents/pharmacokinetics -patients- impaired- renal -function -study -design -
data-analy sis-and-impact -dosing -and. Published: March 2010. Accessed: 30 Jul2020 .
22. ClinicalTr ials.gov. Identifier [STUDY_ID_REMOVED]: A study  to evaluate t he effect of 
dapagliflozin on renal outcomes and c ardio vascular mortality  in patients with chronic 
kidney  disease (Dapa -CKD) . Available 
from :https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. Jan 2017. Accessed :
30Jul
2020.
23. ClinicalTrials.gov. Identifier [STUDY_ID_REMOVED]: 
EMPA -KIDNEY ( the study  of heart and 
kidney  protection with empagliflozin ) Available from: 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. July  2018. Accessed : 30Jul2020.
24. Perkovic V ,Jardine M J, Neal B, et al. Canagliflozin andrenal outcomes intype
2 
diabetes andnephropathy . N Engl J Med. 2019; 380(24):2295 -306.
25. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception and collection of pregnancy  information from female partner: update. 
Clin Transl Med 2016
;5(1):23-37.
26. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management 
of Patients with Confirmed Coronavirus Disease (COVID- 19). 
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical -guidance -management -
patients.html . Updated: 10 Sep tember 2020. Accessed : 21 September 2020.

PF-06882961
Protocol C3421012
Final Protocol, 13 October 2020
PFIZER CONFIDENTIAL
Page 9327. Centers for Disease Control and Prevention. Overview of Testing for SARS -CoV -2 
(COVID -19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-ov erview.html .
Updated: 18 September 2020. Accessed :
22 Septemb er 2020.
28. European Medicines Agency .
Guideline on the evaluation of the pharmacokinetics of 
medicinal products in patients with decreased renal function. Procedue No. 
EMA/CHMP/[ZIP_CODE]/2014. Availabl e from: 
https://www.ema.europa.eu/en/documents/scientific- guideline/guideline -evaluation -
pharmacokinetics -medicinal -products -patients- decreased -renal -function_en.pdf. 
Published: 01 July 2016. Accessed: 30 Jul 2020.
